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1. INTRODUCTION 
 
Parkinsonism is a hypokinetic movement disorder comprising symptoms of 
akinesia (slowness and fatiguing of movement) and rigidity which are often 
accompanied by tremor and postural instability. There are many causes of 
parkinsonian syndromes, among which Parkinson’s disease (PD) is the most 
common. The age-adjusted prevalence of PD in Estonia was reported to be 152 
per 100,000 population; the prevalence rate was higher in older age groups (1% 
among people over 60 years of age), but there were no cases younger than 40 
years of age [Taba and Asser, 2002]. In addition to neurodegenerative diseases 
such as PD, drugs, structural lesions, cerebrovascular diseases, neuroinfections, 
and neurotoxins can induce parkinsonism [Cersosimo and Koller, 2006].  
Since the late 1990s, several young adults with a parkinsonian syndrome of 
unknown etiology have been referred to neurologists in Estonia. It was determined 
that these patients had injected a home-made psychostimulant mixture derived from 
combining Sudafed (pseudoephedrine), a nasal decongestant, with potassium 
permanganate as the oxidant. In the reaction pseudoephedrine was converted into 
ephedrone (methcathinone), and the final mixture also contained high con-
centrations of manganese (Mn), a toxic by-product of the synthesis.  
Mn is an essential element for biologic functions in humans, but excessive 
exposure to this compound can be toxic. Mn toxicity is well known to induce 
parkinsonism called manganism. However, overt clinical manganism is rarely 
seen in current clinical practice. Mn intoxication usually occurs via inhalation 
and results from chronic occupational exposure. In most cases, Mn homeostasis 
is effective and neurotoxicity is rare. Patients with prolonged and excessive 
exposure or those with compromised liver function are potentially more 
vulnerable to Mn toxicity [Jankovic, 2005]. 
Prior to this study, there were no reports of parkinsonsim in ephedrone 
abusers in the international literature. Although amphetamine-like drugs have 
toxic effects on dopaminergic receptors, parkinsonism is not a typical feature of 
psychostimulant abuse [Guilarte, 2001]. Addiction as a potential cause of 
manganism had not been mentioned previously.  
Ephedrone abuse is an important cause of parkinsonism among young 
Estonian patients. We describe the typical clinical picture and natural history of 
the syndrome. Neuroimaging and laboratory studies were performed to find 
biomarkers of exposure and clarify the pathogenesis of the neurological 
damage. In our cohort, the syndrome resembles classic Mn intoxication and 
differs from idiopathic PD. In former ephedrone abusers there are no specific 
laboratory or imaging findings. Diagnosis depends on the typical clinical picture 
and previous drug abuse history. 
Ephedrone abuse may cause permanent neurological damage and severe 
disabilty. The prognosis of the parkinsonian syndrome in the ephedrone users is 
poor, as there is no curative therapy. It is alarming that instructions to prepare this 
highly neurotoxic mixture are available on the Internet. There is considerable 
public health concern if intravenous ephedrone use spreads to larger populations. 
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2. LITERATURE REVIEW 
 
Manganese is an essential trace metal. It is necessary for a multitude of func-
tions, including skeletal system development, energy metabolism, activation of 
certain enzymes, nervous system function, and reproductive hormone function, 
and is an antioxidant that protects cells from damage due to free radicals. The 
most important source of Mn for the general population is diet, and the average 
intake of Mn from food ranges from 2 to 9 mg/d [Santamaria and Sulsky]. 
Under normal dietary consumption, systemic homeostasis of Mn is maintained 
via tight homeostatic control of both gastrointestinal absorption and biliary 
excretion. Exposure to high oral, parenteral or ambient air concentrations of Mn 
can result in elevations in tissue Mn levels [Aschner and Aschner, 2005].  
 
 
2.1. Manganese neurotoxicity 
Chronic Mn poisoning was first reported by James Couper in 1837 in five men 
who worked in a manganese ore-crushing plant in France [Couper, 1837]. Mn 
neurotoxicity was subsequently reported in miners [Cotzias et al., 1968; Mena 
et al., 1967; Rodier, 1955], smelters [Huang et al., 1989; Wang et al., 1989], 
welders [Koller et al., 2004; Tanaka and Lieben, 1969] and workers involved in 
the manufacture of dry-cell batteries [Emara et al., 1971]. Mn toxicity has been 
described in patients receiving long-term parental nutrition [Ejima et al., 1992], 
drinking contaminated water [Kondakis et al., 1989] and following potassium 
permanganate ingestion [Holzgraefe et al., 1986]. Manganism is also associated 
with chronic liver disease [Spahr et al., 1996], as the excretion of manganese is 
markedly impaired, with subsequent accumulation in the brain. Iron shares 
similar absorption mechanisms with essential divalent metals, particularly Mn. 
Blood Mn concentration is elevated in iron deficiency anemia patients [Kim et 
al., 2005]. Iron deficiency can be a risk factor for Mn accumulation in the 
central nervous system. Recently, inherited syndrome of hepatic cirrhosis, 
dystonia, polycythemia, and hypermanganesemia in cases without environ-
mental Mn exposure has been reported [Tuschl et al., 2008] and the cause was 
identified as an autosomal recessive mutation in SLC30A10 [Tuschl et al., 
2012]. 
 
2.1.1. Clinical features and natural history 
Manganism is characterized by symmetric bradykinesia, rigidity, postural 
instability, gait disturbance, difficulty walking backward, micrographia, masked 
face, hypophonia and dysphonia. Dystonia is a common and early feature, 
usually presents as facial grimacing, hand dystonia and/or a peculiar “cock 
gait”. Tremor is less common and tends to be action or postural. In early stages 
of manganese intoxication psychiatric symptoms including irritability, mania, 
uncontrollable laughter, compulsive or aggressive behaviour, hallucinations and 
11 
cognitive disorder have been described [Cersosimo and Koller, 2006; Guilarte, 
2010] 
Serial follow-up studies of previous chronic manganese intoxication patients 
were conducted in a small group of Taiwanese ferromanganese smelters. Their 
parkinsonian symptoms showed rapid progression during the initial 10 years, 
followed by a plateau during the following 10 years [Huang et al., 1998; Huang 
et al., 2007; Huang et al., 1993].  
 
 
2.1.2. Treatment 
Different effects of levodopa (L-dopa) therapy have been reported in patients 
with manganese-induced parkinsonism. Some patients had good response to L-
dopa in earlier reports [Greenhouse, 1971; Mena et al., 1970], but a double-
blind, placebo-controlled trial of L-dopa in Taiwanese smelters showed no 
benefit [Lu et al., 1994].  
Chelating treatment with ethylenediaminetetraacetic acid (EDTA) reduced 
blood Mn levels in acutely poisoned patients and had therapeutic benefit if 
patients were removed from exposure at early stages of disease [Hernandez et 
al., 2006]. Another study showed also that the Mn concentration in blood 
decreased, however the clinical symptoms did not improve [Huang et al., 1989]. 
Sodium para-aminosalicylic acid (PAS), which is used to treat tuberculosis, has 
been found to be effective in a few patients with severe manganism, probably 
due to chelating properties [Ky et al., 1992]. 
 
 
2.1.3. Pathology and pathogensis 
A limited number of autopsy studies have been performed in patients with 
chronic manganese intoxication. They demonstrate a consistent pattern charac-
terized by neuronal loss and reactive gliosis in the globus pallidus (GP) (parti-
cularly the internal segment) and substantia nigra pars reticulata with sparing of 
the substantia nigra pars compacta and an absence of Lewy bodies. This stands 
in contrast to idiopathic PD, where neuronal loss in the substantia nigra pars 
compacta and the presence of Lewy bodies is a neuropathological hallmark of 
the disease. The putamen, caudate and subthalamic nucleus are affected to a 
lesser extent. Involvement of other regions, such as the cortex, thalamus, hypo-
thalamus and red nucleus have also been reported [Bernheimer et al., 1973; Perl 
and Olanow, 2007; Yamada et al., 1986]. 
Recent studies in non-human primates provide neuropathological evidence 
of frontal cortex involvement in Mn neurotoxicity, including diffuse amyloid-β 
[Guilarte et al., 2008b] and α-synuclein aggregation [Verina et al., 2013] 
Mn-induced neuronal toxicity is mediated by disruption of mitochondria 
initiating both apoptosis and necrotic cell death via formation of reactive oxy-
gen species. Mn homeostasis in all tissues, including the central nervous system 
is maintained by several mechanisms including the divalent metal transporter 
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(DMT1), which is considered to be the major transporter for Mn. In the basal 
ganglia DMT1 levels are the highest in the CNS [Roth, 2009]. Mn exposure is 
not associated with dopamine neuron loss, but with the inability of dopami-
nergic neurons to release dopamine [Guilarte et al., 2008a]. Besides dysfunctio-
nal dopaminergic system alterations in the biology of other neurotransmitters, 
such as glutamate, γ-aminobutyric acid (GABA) and norepinephrine (NE) have 
been reported [Aschner et al., 2009]. 
 
 
2.1.4. Biomarkers of exposure 
Many occupational studies have been conducted to determine whether Mn in 
the blood compartment (whole blood, plasma, or serum) can serve as biomarker 
of exposure. In general, these studies appear to suggest that blood Mn con-
centration serves as a reasonable indicator of exposure on a group basis; reflects 
recent, active exposure; and appears to be a modest indicator for distinguishing 
Mn exposed workers from control subjects at the individual level [Zheng et al., 
2011]. 
Studies have attempted to use hair Mn concentration as a measure of cumu-
lative or past exposure providing an average of hair growth period. The average 
value of Mn in hair tended to increase in workers with increased years of 
employment [Zheng et al., 2011]. Hair measurements have several limitations. 
In inhalational exposure there is a potential for external contamination. Mn hair 
concentration has a relatively great background variation [Bader et al., 1999]. 
Increased T1 MRI signal in the basal ganglia is a biologic marker of man-
ganese accumulation in the brain tissue (see the next paragraph). 
 
 
2.1.5. Neuroimaging 
Mn has paramagnetic properties, causing shortening of the T1 relaxation time and 
signal intensity (SI) increase on T1-weighted magnetic resonance imaging (MRI). 
There are no alterations on T2 weighted images. Therefore MRI has been used to 
estimate Mn accumulation in brain tissue. Symmetric T1 hyperintensity in the 
basal ganglia, especially in globus pallidus were first reported in a patient with 
occupational Mn intoxication [Nelson et al., 1993]. Similar T1 hyperintensities 
have been observed in patients receiving total parenteral nutrition [Mirowitz et al., 
1991] and in patients with liver cirrhosis [Krieger et al., 1995; Park et al., 2003]. 
Increased signal intensities on T1-weighted images reflect recent exposure to Mn 
and these MRI changes usually disappear within one year following the 
withdrawal from occupational exposure [Huang et al., 1998; Kim et al., 1999; 
Nelson et al., 1993]. Hyperintense globus pallidus is also present in most patients 
with advanced liver disease and is reversible 10 to 20 months after transplantation 
when liver function returns to normal [Pujol et al., 1993]. 
Direct T1 relaxation time measurement has been shown to be a better 
indicator of low tissue Mn level than visual assessment of SI or the use of a 
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pallidal index (signal intensity ratio of globus pallidus relative to the frontal 
white matter) in T1-weighted images [Choi et al., 2007]. 
Functional imaging studies in Mn-exposed humans with fluorodopa positron 
emission tomography (PET) [Kim et al., 1998; Shinotoh et al., 1997; Wolters et 
al., 1989] or single-photon emission computed tomography (SPECT) with a 
dopamine transporter (DAT) radioligand to access dopamine terminal integrity 
in striatum have been normal or with slightly reduced uptake [Huang et al., 
2003]. Severe asymmetric reduction in striatal F-dopa uptake, reported in two 
welders with occupational Mn exposure [Racette et al., 2001] was probably due 
to coexisting idiopathic PD. 
Workers with Mn-induced parkinsonism had normal iodobenzamide (IBZM) 
SPECT [Hernandez et al., 2006] or small decrease in D2 receptors measured by 
PET with raclopride [Shinotoh et al., 1997]. Markedly decreased D2 receptor 
density using methylspiperone PET was noted in a case with chronic manga-
nism [Kessler et al., 2003]. 
New evidence from non-human primate studies indicates that besides the 
basal ganglia, also frontal white matter and cortical structures are susceptible to 
Mn-induced neurotoxicity [Guilarte et al., 2006].  
Information about regional brain metabolism in manganism is limited. In 
two Mn intoxicated rhesus monkeys, no significant changes were found on 
fluorodeoxyglucose 
(FDG) PET [Shinotoh et al., 1995], but four humans with mild manganism 
showed decreased cortical metabolism [Wolters et al., 1989]. 
 
 
2.1.6. Gene expression 
Gene expression profiling using whole-genome microarray screening is a well-
established technology to obtain a snapshot of the complex response variables 
(transcriptome) in biological systems. Expression profiling has great potential 
for examining molecular pathogenesis and biomarkers of disease. It is a relati-
vely easy to use technology which gives a genome-wide overview of the mole-
cular changes during pathological conditions. Peripheral blood gene expression 
has been used as a surrogate fingerprint of cerebral neurological diseases 
[Davies et al., 2009; Mohr and Liew, 2007; Sharp et al., 2006; Sullivan et al., 
2006]. The resulting profile is a complex description of the molecular pheno-
type and could be used to analyze different acute and chronic conditions. 
In a genome-wide study on primary human astrocytes, Mn-induced changes 
were reported in genes involved in inflammation (upregulated), DNA repli-
cation, and repair (downregulated) [Sengupta et al., 2007]. Gene expression 
studies in the frontal cortex of non-human exposed to Mn showed gene 
expression changes mainly associated with apoptosis, cholesterol metabolism 
and transport, axonal/vesicular transport, inflammation/immune response, cell 
cycle/ DNA repair and biosynthesis, and protein folding and degradation 
[Guilarte et al., 2008b].  
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2.2. Drug abuse and movement disorders 
2.2.1 MPTP 
Historically, intravenous use of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
(MPTP), also known as a “synthetic heroin”, has caused a severe parkinsonian 
syndrome with rigidity, hypokinesia, gait disorder, and hallucinations within 
some weeks after starting injections of the drug [Ballard et al., 1985; Langston 
et al., 1983]. In [18F]fluorodopa PET, there was a reduction of dopaminergic 
function in the caudate and putamen in MPTP users and L-dopa therapy was 
effective [Snow et al., 2000]. Discovering of the ability of MPTP to produce 
selective nigral cell degeneration and parkinsonism in humans has probably 
been the greatest advance in experimental models of PD [Jenner, 2008]. 
 
 
2.2.2 Amphetamine-like psychostimulants  
Amphetamine and the amphetamine-like psychostimulants methamphetamine, 
cathinone and methcathinone (Fig. 1) bind to dopamine, noradrenaline, and to a 
lesser extent serotonin transporters located on neuronal cell membranes. Trans-
porters pump these drugs into the neuron where they are taken up by vesicular 
monoamine transporters. Amphetamines disrupt the proton gradient which 
normally keeps monoamines within the vesicle causing monamines leaving the 
vesicle and accumulate in the cytoplasm where they are reverse-transported out 
of the cell through the same transporters that pumped amphetamines into the 
cell [Fleckenstein et al., 2007]. In addition to increasing their release, ampheta-
mines also decrease monoamine reuptake and enzyme degradation. The net 
result is that amphetamine-like psychostimulants cause a rapid and sustained 
increase in the extracellular concentrations of monoamines [Suzuki et al., 1980]. 
With repeated use in both humans and experimental animal models, 
amphetamines deplete the brain’s stores of dopamine and damage dopamine and 
serotonin nerve terminals. Increases in intra and extracellular concentrations of 
dopamine set off a cascade of events including oxidative stress, neuroinflam-
mation, and excitatory neurotoxicity – the net result of which is neurotoxicity 
[Yamamoto et al., 2010]. 
Cathinone is the principal active constituent present in the leaves of the khat 
shrub (Catha edulis). The stimulant effects have led khat to be known as a 
'natural amphetamine'. Chewing the leaves of the khat plant is common in 
certain countries of East Africa and the Arabian peninsula. Synthetic derivatives 
have been abused for their amphetamine-like stimulant effects, most notably 
methylone, methcathinone (ephedrone), and 4-methlymethcathinone (mephe-
drone). Methcathinone was first synthesized in 1928. It was used in the Soviet 
Union during the 1930s and 1940s as an anti-depressant. It has been used as a 
recreational drug in the Soviet Union from the 1970s and subsequently in the 
USA in the early 1990s. In 1994, methcathinone was added to Schedule I of the 
UN Convention of Psychotropic Substances [Kelly, 2011]. 
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Figure 1. Amphetamine and cathinone derivates 
 
 
Prolonged release of central monoamines and activation of the sympathetic 
nervous system can cause acute neurologic complications like cerebral hemor-
rhage and agitation [Schep et al., 2010]. 
Chronic methamphetamine abuse is associated with deficits in neuropsycho-
logical testing, especially in episodic memory and executive function [Scott et 
al., 2007]. Methamphetamine abusers also suffer from mental illnesses with 
anxiety, depression and psychosis [Darke et al., 2008].  
A potential complication of amphetamine-induced damage to the dopami-
nergic nervous system is the development of dyskinesias and choreoathetoid 
movements [Rhee et al., 1988]. The symptoms usually disappear within a week 
when the drug is discontinued, but may remain for years [Lundh and Tunving, 
1981]. 
Similarly to PD patients, amphetamine users may develop punding (non-goal 
directed repetitive activity) [Schiorring, 1981]. Though several animal and 
human studies have shown that amphetamines cause alterations in striatal 
dopaminergic neurotransmission, parkinsonism is not a feature of amphetamine 
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abuse [Guilarte, 2001]. There are several hypotheses to explain the discrepancy. 
Methamphetamine abuse causes alterations in dopaminergic nerve terminals, 
not in the cell bodies. Methamphetamine users have greater dopamine 
reductions in caudate compared to the putamen, a pattern opposite to that of PD 
[Moszczynska et al., 2004]. Another explanation is that damaged dopaminergic 
nerve terminals recover with abstinence [Volkow et al., 2001a] or the reduced 
dopamine transporter levels are a compensatory response to increased levels of 
extracellular dopamine. Vesicular monoamine transporter-2 (VMAT2), which is 
known to be resistant to drug-compensatory regulation, is not reduced in 
abstinent methamphetamine abusers [Johanson et al., 2006]. However, some 
studies have shown an increased risk for developing PD in amphetamine 
abusers [Callaghan et al., 2010; Christine et al., 2010]. 
 
 
2.2.3 Ecstasy 
Ecstasy is the colloquial name given by its users to 3,4-methylene-dio-
xymethamphetamine (MDMA). It is a ring-substituted amphetamine derivative 
that is also related to the hallucinogenic compound mescaline. MDMA binds to 
all three of the monoamine presynaptic transporters with highest affinity for the 
serotonin transporter. Chronic ecstasy use causes depletion of serotonin, which 
has subtle but important long-term effects on cognition and mood [Morton, 
2005]. A few cases of parkinsonism have been reported in ecstasy users 
[Kuniyoshi and Jankovic, 2003; Mintzer et al., 1999; O’Suilleabhain and Giller, 
2003], but in these cases MDMA use was not toxicologically verified. It is 
possible that the young-onset parkinsonism and drug exposure were just coinci-
dental [Kish, 2003]. 
 
 
2.2.4 Cocaine 
Cocaine is derived from the leaves of the coca plant. It enhances dopaminergic, 
noradrenergic, and serotonergic neurotransmission by blocking reuptake of 
these monoamines. Neurological complications are more common with the 
smokable alkaloidal cocaine “crack”, as it allows much higher doses than with 
snorted cocaine hydrochloride. Stereotyped hyperkinetic movements (“crack 
dancing”) are well recognized by cocaine users and there are occasional reports 
of acute reversible parkinsonism in the acute phase of intoxication [Bartzokis et 
al., 1999; Daras et al., 1994]. Acute dystonia and chorea following cocaine use 
usually last from minutes to a few days [Brust, 2010], but a case with persistent 
dyskinesias after 20 months of abstinence has been described [Weiner et al., 
2001]. The use of potassium permanganate in the processing of coca-leaf 
extraction, can also lead to manganese intoxication [Ensing, 1985]. 
 
 
17 
2.3 Manganese-Ephedrone abuse 
It is difficult to estimate the scope of ephedrone abuse and the prevalence of 
parkinsonism among drug addicts. There are approximately 13,800 intravenous 
drug users in Estonia, 10,000 of them living in Tallinn and its neighbouring 
areas, and 2,500 in the Northern-Eastern part of Estonia [Uusküla et al., 2007]. 
In a survey of risk behaviours in these areas, 700 intravenous drug users in 
Tallinn and Eastern Estonia were interviewed, yielding the following results: 
11% of the participants reported ephedrone use in their history, 1.3% were 
current users, and in 0.9% ephedrone was the main drug of abuse [Lõhmus et 
al., 2008]. Based on these findings, it could be estimated that there could be 
approximately 100 persons injecting ephedrone as the main drug of abuse in 
Estonia. Ephedrone abuse is a common cause of parkinsonism among Estonian 
patients younger than 40 years of age. 
The first cases of “ephedrone encephalopathy” were described in Russian 
literature 25 years ago [Lukacher et al., 1987]. Parkinsonian syndrome in 
ephedrone users had not been depicted in the international literature before this 
study. Although both Mn and ephedrone (similarly to other psychostimulants) 
are toxic to the dopaminergic nervous system, parkinsonism has been described 
only in association with Mn intoxication. Aims of the present study were to 
characterize the clinical picture and course of the syndrome in intravenous 
ephedrone users in Estonia, and to confirm the presumed neurotoxicity of Mn in 
the pathogenesis.  
Following our first report [Sikk et al., 2007], several cases of parkinsonian 
syndrome in ephedrone users have been reported in Eastern Europe as well as 
among immigrants from Western Europe and Canada. Clinical characteristics 
and MRI data from the case reports are summarized in Table 1 [Sikk et al., 
2011]. The first neurological symptoms – usually gait disturbance and slurred 
speech – have occurred anywhere from only a few months after the beginning 
of ephedrone injections [Sanotsky et al., 2007] up to 17 years later [Stepens et 
al., 2008], but generally they have emerged within the first few years. The most 
commonly reported neurological findings were postural instability with retro-
pulsion and falls, gait disturbance, hypomimia, limb and face dystonia, 
dysarthria, hypophonia, and symmetric bradykinesia. Less frequently described 
symptoms included limb and axial rigidity, gait freezing, postural and resting 
tremor, micrographia, apraxia of eyelid opening, some slowing of vertical 
saccades, pathological laughter, palilalia, and primitive reflexes. Alhough 
hyperactive deep tendon reflexes were commonly found, pathological reflexes 
were mentioned only in one case [Colosimo and Guidi, 2009]. Few cases had 
oromandibular dyskinesia, blepharospasm [Varlibas et al., 2009], myoclonus 
[Levin, 2005], or restriction of vertical saccadic eye movements [de Bie et al., 
2007].  
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The scores of the Mini Mental State Examination were normal. More extensive 
neuropsychological testing showed mild executive cognitive impairment, in-
cluding bradyphrenia, attenuated attention, reduced working capacity, decreased 
phonetic verbal fluency, and tendency for impulsiveness [Colosimo and Guidi, 
2009; Djamshidian et al., 2012; Levin, 2005; Selikhova et al., 2008; Yildirim et 
al., 2009]. 
Generally, the syndrome is unresponsive to L-dopa and other antiparkin-
sonian medication, and there are no other effective treatments that could conti-
nuously improve parkinsonian or dystonic symptoms in the ephedrone users. 
Even when mild improvement has been observed, it has been short-term, and 
the condition may worsen progressively despite of discontinuation of the drug 
injections. 
MRI of the brain in active ephedrone users showed symmetrical hyper-
intensity on T1-weighted images in the globus pallidus and substantia nigra pars 
reticulata. Less frequently involved structures were subthalamic nucleus, 
substantia innominata, putamen, caudate, anterior midbrain, pontine tegmentum, 
and dentate nucleus. 
  
21 
3. AIMS OF THE STUDY 
 
1. To characterize the clinical syndrome in intravenous ephedrone users: assess 
clinical severity, and quality of life (Papers I and IV). 
2. To assess the course and prognosis of the neurological syndrome in 
ephedrone users (Paper IV). 
3. To find biomarkers of exposure (Paper IV). 
4. To describe findings from MRI and functional neuroimaging (Papers II and 
IV). 
5. To explore the molecular pathogenesis of the syndrome by performing gene 
expression analysis (Paper III). 
  
22 
4. MATERIAL AND METHODS 
4.1. Study population 
Subjects were identified from the neurology and psychiatry departments of 
Estonian hospitals, from addiction rehabilitation centers, and from information 
provided by other drug addicts. Written informed consent was obtained from all 
subjects. The study was approved by the Ethics Review Committee on Human 
Research of the University of Tartu. Patient involvement in different studies in 
summarized in Table 2. 
 
 
4.2. Clinical examination 
Patients underwent general neurological examination and most of the cases 
were video-taped. Detailed information about co-morbidities, drug use history 
and appearance of first symptoms was gathered.  Disease severity was scored by 
the Unified Parkinson’s Disease Rating Scale (UPDRS); Hoehn-Yahr (HY) 
Rating Scale;  and Schwab and England (SE) Activities of Daily Living (ADL) 
Scale [Fahn S et al., 1987]. 
UPDRS is the most widely used standardized scale to assess parkinsonism. It 
is designed to monitor PD disability and impairment. Parts I (mentation, 
behavior and mood), II (ADL) and III (motor examination) contain 44 questions 
each measured on a 5-point scale (0–4). Total UPDRS score is the combined 
sum of parts I, II, and III: 0 (not affected) to 176 (most severely affected). Part 
IV (complications of therapy) was not performed. 
HY scale provides a global assessment of disease severity, based on clinical 
findings and functional disability. The scale includes stages from 0 (no signs) to 
5 (wheelchair bound or bedridden unless aided) to indicate the relative level of 
disability. 
SE ADL scale is a means of assessing a person’s ability to perform daily 
activities in terms of speed and independence through a percentage, with 100% 
indicating total independence, falling to 0%, which indicates a state of complete 
dependence.  
To evaluate health related quality of life, Parkinson’s Disease Quality of Life 
Questionnaire (PDQ-39) was completed by the patients [Peto et al., 1995]. It 
comprises 39 questions, relating to eight key areas of health and daily activities, 
including both motor and non-motor symptoms.  It is scored on a scale of 0 to 
100, with lower scores indicating better health and high scores more severe 
symptoms.  
In order to examine cognitive function, the Mini-Mental State Examination 
(MMSE) was used [Folstein et al., 1975]. Scores of 25–30 out of 30 are 
considered normal. 
A standardized acute L-dopa challenge test with 200/50 mg levodopa/ 
carbidopa was performed in 4 former users to evaluate treatment response after 
one hour.  
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4.3. Follow-up 
From among the 38 subjects seen during the first examination, two had died  by 
the time of the next contact, one had moved abroad, one declined further 
participation, and 10 were not traceable because they no longer had the same 
phone number or address. Final follow-up evaluations of 24 subjects were 
carried out 21±15 months after the initial examination, including 12 former 
(26±18 months) and 12 active users (15±7 months). Three of the 12 former 
users were defined as active users during the first study, other 9 had been drug 
free for 3.8±2.4 years at baseline. 
 
 
4.4. Laboratory synthesis of the mixture 
Laboratory synthesis of the mixture and Mn concentration measurements were 
performed at the Department of Physical and Analytical Chemistry of Uppsala 
University. 
According to the information provided by the interviewed patients, the 
following recipe is regularly used in the preparation of ephedrone: a package 
(12 tablets) of the nasal decongestant Sudafed, containing 60 mg pseudo-
ephedrine hydrochloride, 1–2 mL 30% acetic acid and “a point of the knife” of 
potassium permanganate were poured into 60–100 mL of boiling water. The 
mixture was left to cool down for about 10 minutes and filtered through a cotton 
pad. The solution was used for 8–20 mL intravenous injections at irregular 
intervals many times a day. 
To evaluate the chemical reactions and yields of the reported procedure, the 
following synthetic and analytical investigations were performed: to 1 tablet 
Sudafed (Pseudoephedrine hydrochloride [(+)-(1S,2S)-2-methylamino- 
1-phenylpropan-1-ol, C10H15NO, CAS 90-82-4, Mw 165.22] 60mg, 
GlaxoSmithKline Greenford, Middlesex, Great Britain), 0.145 g KMnO4 
(VWR International AB, Stockholm, Sweden),  5 mL  H2O at 100° C and  
0.125 mL 30% acetic acid (p.a., Merck, Darmstadt, Germany) was added and 
the solution was mixed (vortexed) until the tablet was fully dissolved. The 
solution was left to cool for 10 min before it was filtered through a filter paper 
(Munktell 3, Stora Kopparberg Filter Products, Grycksbo, Sweden). 
Synthesized ephedrone was qualitatively analysed using electrospray mass 
spectrometry (ESI-MS) using a QTRAPTM linear ion trap mass spectrometer 
(Applied Biosystems, MDS SCIEX, Toronto, Canada) equipped with a 
pneumatically assisted Turbospray ionization interface. The software Analyst 
1.4.1 (MDS Sciex, Concord, ON, Canada) was utilized for data acquisition and 
evaluation. The experiments were performed by direct infusion at 10 uL/min, 
employing enhanced mass scan (EMS) configuration. 
The manganese (Mw 54.9) content of the final synthetic mixture was 
analyzed using a SpectroCirosCCD Inductively Coupled Plasma-Atomic 
Emission Spectrometer (ICP-AES) (Spectro Analytical Instruments GmbH&Co, 
26 
Kleve, Germany). Analytical standards for Mn were prepared from certified 
single-element stock solutions and used for calibration. 
 
 
4.5. Laboratory tests 
4.5.1. Virology, hepatic function, iron levels 
Subjects (n=28) were tested for Human immunodeficency virus (HIV) (anti-
HIV antibodies), Hepatitis C virus (HCV) (anti-HCV antibodies)  and Hepatitis 
B virus (HBV) (HBsAg and anti-HBc antibodies). For evaluation of hepatic 
function bilirubin and alanine transaminase levels were measured (n=28). For 
detecting  iron deficiency serum ferritin, iron and transferrin levels were 
measured (n= 25). 
 
 
4.5.2. Plasma and hair manganese concentration 
Plasma (n=26) and hair (pooled pubic+scalp) (n=17) Mn concentration was 
analyzed using a SpectroCirosCCD Inductively Coupled Plasma-Atomic Emis-
sion Spectrometry (ICP-AES) (Spectro Analytical Instruments GmbH&Co, 
Kleve, Germany). Hair samples from 21 age- and sex-matched Estonian 
inhabitants (from the Ida-Viru county) were also examined.  
 
 
4.6. Statistical analysis 
Data analyses were performed with Stata software version 10. Continuous data 
were expressed as mean and standard deviation (SD). Differences between 
study groups were compared with unpaired t-tests, for single variable deter-
mination upon repeated evaluation paired t-test was applied. Bivariate relation-
ships were assessed with Pearson’s correlation coefficient. All p-values were 
two-tailed; p-values <0.05 were considered statistically significant. 
 
 
4.7. Neuroimaging 
MRI with T1 relaxation time measurements, DAT SPECT and FDG PET were 
performed in 4 former ephedrone users (abstinence for at least 4 years) at 
Uppsala University Hospital, MRI was evaluated by neuroradiologist Raili 
Raininko, DAT SPECT and FDG PET by Torsten Danfors. IBZM SPECT (n=8) 
and MRI (n=11, including active users) were performed in North Estonian 
Medical Center, IBZM SPECT was evaluated by Malle Paris and MRI by Äli 
Roose. 
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4.7.1. MRI with T1 relaxation time measurements 
MRI was performed with a Philips Gyroscan Intera MR imager operating at  
1.5 T. All slices were 5 mm thick. T1-weighted spin echo images were obtained 
in sagittal (TR/TE 501/12 ms), axial (TR/TE 599/13 ms) and coronal (TR/TE 
500/19 ms) planes and T2-weighted fast SE (FSE) images in axial (TR/TE 
5075/100 ms) and coronal (TR/TE 6099/100 ms) planes. Diffusion-weighted 
images were obtained in an axial plane with a FLAIR sequence (TR/TE/TI 
10000/140/2000 ms) using b values of 0 and 1000 s/mm2. Apparent diffusion 
coefficient (ADC) maps were calculated. The images were evaluated visually 
by an experienced neuroradiologist. 
Signal intensities (SI) were measured in the T2-weighted axial images in the 
lateral globus pallidus, anterior putamen, caput nuclei caudati, thalamus and 
frontal white matter bilaterally.  Cerebrospinal fluid (CSF) in the anterior part of 
the frontal horns was used as an SI reference. The SI of the white matter was 
also measured in the centrum semiovale bilaterally by using CSF on the frontal 
convexity in the same slice as an SI reference. The SI measurements were 
repeated two weeks apart and the means were used in the calculations.  
For T1 relaxation time measurements, an axial 5-mm-thick slice was 
obtained through the basal ganglia using a field of view 250 x 150 mm and an 
in-plane resolution of 0.98 x 1.42 mm.  A Lock-Looker technique was used. 
The 180 degree pulses were repeated every 3400 ms with 40 alphapulses of 6 
degrees at 25 ms spacing between the alphapulses. A monoexponential fit was 
performed to the real signal in every pixel to determine the T1 value in each 
pixel. The fitting algorithm included corrections for noise and imperfect 180 
degree pulses. The T1 relaxation times were measured by using a NICE (Nordic 
NeuroLab AS, Oslo, Norway) software in the lateral globus pallidus, anterior 
putamen, caudate head and frontal white matter bilaterally. The measurements 
were repeated in the globi pallidi, except in one control, by another observer 
and the means of the two measurements were used in analysis. 
Four healthy age- and sex-matched volunteers were examined as controls. In 
the measurements, the values beyond 2 SD were considered pathological. 
 
 
4.7.2. DAT SPECT  
SPECT imaging took place 3.5 to 4 hours after intravenous injection of 123I 
Ioflupane (185 MBq, DaTSCAN GE Healthcare, Amersham, UK). Before the 
administration, the patients received iodide preparation to minimize radiation 
exposure to the thyroid gland.  A Siemens E.CAM (2001) with a low energy 
high resolution (LEHR) collimator and software eSoft 6.0 were used. For all 
acquisitions 120 projections, 360 degrees rotation, 30 s per projection and a 
matrix size of 256 x 256 was used.  
Data were reconstructed with the HERMES software v4.5-B (HERMES 
iterative reconstruction, HOSEM) (Hermes Medical Solutions, Nuclear Diag-
nostics AB, Stockholm).  
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Further image processing was performed using an in-house developed soft-
ware according to the following: First each scan was spatially normalized to fit 
a normal template defined in Montreal Neurological Institute (MNI) space using 
a fully automated method. Then a volume of interest (VOI) template was 
applied to the data and counts in regions corresponding to the head of the 
caudate nucleus and the anterior and posterior putamen were extracted. Striatal 
Binding Ratios (SBRs) were computed by normalising the count data in the 
Striatal VOIs against the mean value in a reference region located in the 
occipital and temporal lobe. In addition, the ratio between putaminal and 
caudate uptake was computed.  
SPECT images were visually classified by experienced nuclear medicine 
physicians as normal or abnormal. A normal pattern was defined as a symmetric 
bilateral intense uptake in both the caudate nucleus and putamen. An abnormal 
pattern as either an asymmetrical uptake with reduced uptake in putamen in one 
hemisphere; or symmetrically reduced putamen activity in both hemispheres; or 
a reduced uptake in both the caudate nucleus and the putamen. The latter 
resulting in a significant reduction in contrast and the visualisation of 
background activity throughout the rest of the image.  
 
 
4.7.3. FDG PET 
Patients fasted overnight before FDG PET scanning. All scans were performed 
with the subject’s eyes open and in a dimly lit room with minimal auditory 
stimulation. All four subjects were scanned using a Siemens ECAT EXACT H+ 
scanner after an i.v. injection of 3 MBq/kg (184-227 MBq) of [18F] FDG. A 15-
min emission scan was acquired 30 min after injection. Image data were 
analysed by a voxel-by-voxel method. All four scans were performed within  
2 weeks. 
All PET scans were spatially normalised to Montreal Neurological Institute 
(MNI) space. This was done by registering each PET scan to the MNI PET 
template using an automated method for inter-individual registration (4). The 
same method was used to spatially normalise FDG scans from 20 healthy 
controls (mean age 69 y). Mean and SD of the spatially normalised control 
scans were then computed on a voxel-by-voxel basis to define an FDG normal 
data base. A computer program was implemented allowing for voxel-based 
comparison of individual PET scans with the FDG normal data base. This 
comparison was made using Z-scores, i.e., by taking the subject’s voxel value 
and subtracting the mean value in the normal data base and then dividing by the 
SD for the corresponding voxel and repeating this for all voxels. The Z-scores 
show by how many SDs the subject’s voxel value differs from the mean. The 
result of this comparison was expressed as Z-score images; one image volume 
for negative Z-scores showing hypometabolism and one with positive Z-scores 
showing hypermetabolism. In the subsequent analysis we used a threshold on 
volume and degree of deviation and only hyper- and hypometabolic regions 
with a volume larger than 0.3 mL and degree of deviation of 3 SD or more were 
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considered. Moreover, due to anatomical variations, hyper- and hypometabolic 
regions located in the cortical or subcortical areas were excluded. Additionally, 
three persons randomly selected from the normal database were evaluated as 
described above. 
 
4.7.4. MRI  
MRI examination was performed in 11 subjects, 4 subjects had repeated MRI 
scans.  
Brain MRI was performed using GE 1.5 T Signa HDx system according to 
standard evaluation protocol using 8 channel neurovascular head coil with slice 
thickness of 5 mm and interval of 1 mm on T1-weighted sequence in sagital, 
coronal and axial planes, T2-weighted sequence in axial plane and FLAIR 
sequence in coronal plane, DWI images with b-value 1000s/mm2.  
In addition to general MRI description, signal hyperintensity on T1- 
weighted sequence in  different anatomical structures was graded in four 
categories: 0 – normal, 1 – mildly hyperintense, 2 – moderately hyperintense, 
and 3 – severely hyperintense (signal intensity agrees with fatty marrow tissue 
signal intensity). 
 
4.7.5. IBZM SPECT 
Single-photon emission computed tomography (SPECT) with iodine-123 
iodobenzamide (IBZM), a ligand for D2 receptors was performed in 8 cases 
using a dual head gamma camera (SPET/CT INFINIA, GE Healthcare) with a 
high resolution collimator. Images were acquired in a step and shoot mode with 
120 equally spaced projections over 360°, taking 40 s per step and using 
128×128 matrix size, with a zoom of 1.0. The energy window was centered on 
159 keV. Image reconstruction was performed using a Butterworth filter, and 
attenuation correction was performed using Chang coefficient. Transversal 
slices were reconstructed parallel to the cantomental plane. The individual 123I-
IBZM occupancy regions of interest (ROIs) were drawn over the striatum and 
the occipital cortex, serving as a reference region. The activity ratios of striatal 
to occipital cortex uptake (S/OC) were used as a semiquantitative measure of 
the relative density of striatal D2 receptors. S/OC ratios previously obtained 
from a control group of 8 patients with idiopatic Parkinson´s disease (IPD) with 
a mean age of 59 years were used for comparison. 
 
 
4.8. Gene expression 
Blood samples from 20 subjects and 20 age- and sex-matched healthy controls 
were collected into Tempus tubes (Applied Biosystems, Foster City, USA). 
Blood was frozen and stored until further processing. RNA extraction from 
whole blood was performed according to the manufacturer’s protocol (PN 
4379228C). After RNA extraction, alpha and beta globin mRNA was depleted 
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with GlobinClear Whole Blood Globin Reduction kit (Ambion, Austin, USA). 
The quality of RNA was analyzed with a Bioanalzer 2100 (Agilent, Santa Clara, 
USA) and gene expression profiling was performed with GeneChip Human 
Gene 1.0 ST Arrays (Affymetrix, Santa Clara, USA) containing probes for all 
exons of 28,869 genes. We analyzed all the genes on the array without any 
filtering for presence/absence cells. 
In order to label the RNA we used the Affymetrix GeneChip Whole 
Transcript (WT) Sense Target Labeling Assay (Affymetrix, Santa Clara, USA), 
which is designed to generate amplified and biotinylated sense-strand targets 
from the entire expressed genome without bias. Briefly, double-stranded cDNA 
was synthesized from 300 ng of total RNA by reverse transcription using 
random hexamers tagged with a T7 promotor primer sequence. The double-
stranded cDNA was subsequently used as a template and amplified by T7 RNA 
polymerase producing many copies of antisense cRNA. In the second cycle of 
cDNA synthesis, random hexamers were used to prime reverse transcription of 
the cRNA from the first cycle to produce single-stranded DNA in the sense 
orientation. This DNA was fragmented with a combination of uracil DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1). DNA 
was labelled by terminal deoxynucleotidyl transferase (TdT) and hybridization 
was performed according to the manufacturer’s protocol. The arrays were 
subsequently washed, stained with phycoerythrin streptavidin and scanned 
according to standard Affymetrix protocol. Images were processed using the 
Affymetrix Expression Console and the MAS 5.0 algorithm was used to 
measure quality control parameters.  
The normalized, background subtracted and modelled expression (Robust 
Multi-array Analysis, RMA) data (GEO accession number GSE28686) were 
further analyzed using a linear model combined with Bayesian moderation for 
standard errors implemented in the Bioconductor limma package of the 
statistical software R (http://www.r-project.org/) [Ihaka and Gentleman, 1996; 
Smyth, 2004]. False Discovery Rate (FDR) was used to address multiple testing 
corrections [Benjamini and Hochberg, 1995; Storey and Tibshirani, 2003]. 
Moderated model calculates B value, which is the log-odd that the gene is 
differentially expressed. B-statistics of zero corresponds to a 50–50 chance that 
the gene is differentially expressed and B-statistics is automatically adjusted for 
multiple testing.  
Eight genes with significant differences and with potentially interesting 
functions from the gene expression profiling data were further analyzed by 
means of real-time PCR (RT-PCR). These genes were: C15orf26, GPR15, 
IGFR1, SNRPN, IFI44L, IFI44, IFI27, and IFNG. RNA was converted into 
cDNA using the High Capacity cDNA Synthesis kit from Applied Biosystems. 
TaqMan assays and Gene Expression Master mix was used for the RT-PCR 
reaction in the SDS 7900 HT system (Applied Biosystems). Sample (20 
controls and 20 methcathinone users in four replicates) comparisons were made 
using Welch's t-test. 
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To define the functional networks of the differentially expressed genes, data 
were analyzed by Ingenuity Pathway Analysis (IPA, Ingenuity Systems, 
www.ingenuity.com). A data set containing Affymetrix probeset identifiers and 
corresponding fold change (log2) values was uploaded. Each gene identifier 
was mapped to its corresponding gene object in the Ingenuity Pathways 
Knowledge Base to generate the list of focus genes. Networks of these focus 
genes were then algorithmically generated based on inter-gene relationships 
manually curated in the Ingenuity database from published studies. Ingenuity 
Pathways Analysis calculates a significance score for each network. The score 
is generated using a p-value calculation, and is displayed as the negative 
logarithm of that p-value. This score indicates the likelihood that the assembly 
of a set of focus genes into a network could be explained by chance alone (e.g. 
score of 2 indicates that there is a 1 in 100 chance that the focus genes are 
together in a network by a random chance). In whole-genome gene expression 
studies scores >8 (p<0,000000001) are considered statistically significant. 
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5. RESULTS 
 
5.1. Study population 
During the period of 2006–2012, we studied 38 intravenous ephedrone users 
(31 men and 7 women) aged between 18 and 58 years (mean age 33 years). 
Majority of the subjects (76%; n=29) came from the Ida-Viru county, with 
additional 7 (18% ) subjects from Tallinn and the Harju county, and 2 cases 
from Tartu. All except one study participant (an Estonian) were Russian 
speakers. The educational level was 9 years or less in 66%, 10 to 12 years in 
32% (vocational or secondary education), and one subject had higher education. 
The rate of unemployment was very high (95%), and in 70% the main income 
was disability allowance. Ten subjects were currently married and in 8 cases 
both spouses were ephedrone users. Most of the subjects were single (58%) or 
divorced (16%). More than half of the subjects lived alone (n=20), 10 with their 
mothers, and 8 had children in their family. At the time of the baseline study, 
two subjects were in prison, one was homeless, and 12 (32%) lived in a 
dormitory. 
 
5.2. Clinical examination 
8–20 ml of ephedrone solution was injected 2 to 30 times per day. As the total 
injected volume and Mn amount in the solution differed between subjects, 
duration of exposure gives the best estimation of the total exposure. The 
average duration of ephedrone use was 4.6±3.9 years (0.25 to 13 years). 
According to the subjects exposure history they were defined as a active (n=20) 
or former users (n=18) (reported abstinence more than one year previously). 
Former users had been drug free 4.9±2.2 years. Ephedrone was the main drug of 
abuse, 55% had also used or tried amphetamine and  63% opiates (heroin, 
fentanyl and poppy liquid). The mean age of starting the ephedrone injections 
was 25 years with a range of 14 to 41 years.  
Based on the history given by the subjects, the first neurological symptoms 
appeared on average 2.8±3.1 years (0.5 to 12 years) after the beginning of 
ephedrone use. The presenting feature was gait disturbance in 14 (37%) cases, 
speech disturbance in 10 (26%) and loss of balance in 9 (24%). 
The average total UPDRS score was 43.3±20.8; within this the mean score 
of part III (Motor Examination) was 28.3±14.7. The total UPDRS score was  
≤ 25 in 20%, 25–49 in 40%, and ≥ 50 in 40% of the patients. The mean value of 
HY staging was 2.9±0.9; the biggest group of patients  (n=19, 50%) were 
categorised as stage III (Figure 2), indicating bilateral disease with postural 
instability and moderate effect on ADL.  
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The average score of SE activities of daily living was 76.2±14.5%, indicating 
not complete independence; more difficulty with some chores; two to three 
times as long in some; must spend a large part of the day with chores. 
Mean score in health related quality of life scale PDQ-39 was 43.4±17.5% and 
the most affected domains were mobility, communication, stigma and emotional 
well-being, the latter was not correlated with the UPDRS score (Figure 4). 
Symptom severity measured by UPDRS, HY and SE was not influenced by 
the duration of exposure, but a positive correlation was observed between the 
duration of exposure and PDQ-39 (worse quality of life with longer exposure) 
(r=0.41; p=0.014). Worse scores in PDQ-39 were also correlated with worse 
results in UPDRS (r=0.61; p<0.001), HY (r=0.58; p<0.001) and SE (r=–0.56; 
p<0.001). HIV status did not affect PDQ-39 scores. 
MMSE cognitive function average score was 28.4±2.0 (min 20). Two 
patients scored below 25, indicating cognitive impairment. 
L-dopa challenge test showed no objective or subjective improvement. 
 
 
 
 
Figure 4. The average score of PDQ-39 domains. *Correlation with UPDRS score 
(p<0.05) 
 
5.3. Follow-up 
Results of follow-up examination are given in Table 3. Worsening of HY stage 
and SE scores reached statistical significance. The changes in all follow-up 
rating scales exept MMSE were significantly bigger if the interval between two 
evaluations was longer than a year. The changes in rating scales between former 
and active users were not different, but active users had a shorter follow-up 
time.  
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users and in controls was not different (1.08±0.4, p=0.56) (Fig. 6). Samples in 
former users were collected on average 4.6±2.9 years after discontinuation of 
ephedrone use. At the individual level there was a large variablity in hair Mn 
level, in the control group the highest value was 4.5 ppm. The concentration of 
Mn in a former user with 8 years of abstinence and normal MRI was 3.7 ppm. 
On the other hand, an active user who had high plasma Mn concentration  
(19.3 ppb), had low Mn level in hair (0.81 ppm). 
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Figure 6. Mn concentration in hair in active and former users, and controls 
 
 
Plasma Mn concentrations were significantly higher (11.5±6.2 ppb) in active 
than in former users (5.6±1.8 ppb), p=0.006. The average plasma Mn con-
centration in subjects (n=5) who reported ephedrone use on the same day when 
the samples were taken was 18.3±5.5 ppb and in the other active users 8.1±2.7, 
p=0.0003. The difference in plasma Mn levels between active users who did not 
report ephedrone use on the same day and former users was much smaller 
(p=0.02) (Fig. 7). 
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Figure 7. Mn concentration in plasma. A – active, ephedrone abuse on the same day;  
B – other active; C – former 
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5.6. Neuroimaging 
5.6.1. MRI with T1 relaxation time measurements 
Visual evaluation did not reveal pathological SI in any patient. Age and gender 
did not affect the T1 relaxation times or T2 SI in the healthy controls and SDs 
were small. In frontal white matter, both the SI on the T2-weighted images and 
the T1 relaxation times were similar in patients and controls. In the basal 
ganglia, some values were beyond two SD of the control values (Table 4). 
 
 
Table 4. MRI measurement values beyond 2 SD of the healthy controls 
 
Patient Change in T1 relaxation times Change in SI on T2-weighted 
images 
Globus 
pallidus 
Putamen Caudate 
head 
Globus 
pallidus 
Putamen Caudate 
head 
1 ↑ (R,L)  ↑ (R) ↑ (L) 0 ↑ (L) 0 
2 ↓ (R,L)  ↓ (R,L) ↓ (R,L) 0 0 ↑ (R,L) 
3 ↓ (R,L)  ↓ (R,L) ↓ (R) 0 ↓ (R) 0 
4 0 0 0 0 0 0 
 
R – right, L – left, 0 – no change beyond 2 SD, ↑ – > +2 SD, ↓ – < –2 SD, SI – Signal 
intensity 
 
 
5.6.2. DAT SPECT 
All four patients were visually classified as having a normal pattern of 123I 
Ioflupane uptake. Also, the striatal binding ratio and the ratio between putamen 
and caudate uptake were estimated as normal (Table 5). 
 
 
Table 5. Striatal dopamine transporter binding ratio 
 
Patient SBR* 
Caudate (R/L) 
SBR* 
Putamen (R/L) 
Putamen/CaudateRatio 
(R/L) 
1 2.54/2.45 2.38/2.30 0.94/0.94 
2 2.97/3.19 2.59/2.51 0.87/0.79 
3 2.34/2.28 2.05/1.94 0.88/0.85 
4 2.19/2.28 1.79/1.75 0.82/0.77 
 
* Striatal Binding Ratios (SBRs) defined as: (uptake in region – non specific uptake)/ 
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All four p
FDG upta
the basal 
areas wer
the patho
increased 
semiovale
the basal 
database h
 
 
 
Figure 8. 
 
Table 6. R
 
Patient 
1 
2 
3 
4 
 
R – right, 
atients show
ke with chan
ganglia, thal
e situated in 
logical areas
uptake was l
, patient 3). 
ganglia and 
ad any signi
FDG PET in P
egional incre
Decrease
Putamen
Internal c
Thalamu
Putamen
Centrum
L – left 
5.6
ed a widesp
ges mainly l
ami, and the 
the transition
 showed a 
ocated in the
No areas of 
thalami (Ta
ficant areas o
atient 3. Dec
ases and decr
 
 (R). Thalamu
apsule (R). P
s (L). Putame
 (R). Internal 
 semiovale (R
39 
.3. FDG P
read, but n
ocated to the
surrounding
 between gr
decreased u
 white matte
significant in
ble 6). None
f pathologica
reased uptake
eases in FDG
s (R.L). Pons
utamen (R) 
n (R) 
capsule (L). 
. L) 
ET 
ot uniform, p
 central part
 white matte
ey and white
ptake of FD
r above the r
creased FDG
 of the subj
l uptake.  
 in the left th
 uptake 
Incr
  
 
Cent
 
athological 
 of the brain,
r (Fig. 8). So
 matter. All 
G. The onl
ight ventricle
 uptake wer
ects selected
alamus 
ease 
rum semiova
pattern of 
 including 
me of the 
but one of 
y area of 
 (centrum 
e found in 
 from the 
 
le (R) 
40 
5.6.4. MRI 
All active users had quite similar findings on MRI T1 weighted images: sym-
metric hyperintensity in globus pallidus, substantia nigra, periaquaductal grey 
matter and cerebral pedunculi, less in putamen, caudate nucleus, dentate nucleus 
and white matter (Table 7, Figure 9). No signal alterations were noted on T2-
weighted, DWI and FLAIR images. No other abnormalities were seen on MRI. 
 
Table 7. MRI findings and plasma Mn concentrations in active and former ephedrone 
abusers 
 Duration of Mn in    
 cessation  plasma   
Case (years)  (ppb)  PAGM SN CP GP NC P WM ND 
1 4  NP  0 0 0 0 0 0 0 0 
2 8  4.6  0 0 0 0 0 0 0 0 
3 8  4.7  0 0 0 0 0 0 0 0 
4 8  4.4  0 0 0 0 0 0 0 0 
5 2.5  10.9  3 2 2 3 1 2 2 2 
6 active  7.1  3 3 3 3 1 2 2 2 
7 active  6.9  3 3 3 3 1 2 2 2 
8 active  NP  3 2 1 3 0 0 2 1 
 3  5.3  0 0 0 0 0 0 0 0 
9 active  7.3  0 1 0 2 0 0 0 0 
 3.5  NP  0 0 0 0 0 0 0 0 
10 active  NP  3 0 3 3 0 0 1 2 
 active  NP  2 0 2 2 0 0 0 1 
11 active  NP  0 0 1 1 0 0 0 0 
 2.5  NP  0 0 0 2 0 0 0 0 
 
PAGM – periaquaductal grey matter, SN – substantia nigra, CP – cerebral peduncles, GP – globus 
pallidus, NC – nucleus caudatus, P – putamen, WM – White Matter, ND – nucleus dentatus, NP – 
not performed, 0 – normal, 1 – mildly hyperintense, 2 – moderately hyperintense and 3 – severely 
hyperintense (signal intensity agrees with fatty marrow tissue signal intensity) 
 A
 B
 
Figure 9. 
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5.6.5. IBZM SPECT 
IBZM SPECT showed normal symmetric tracer uptake in striatum. The average 
S/OC ratio in in subjects (1.85±0.2) (Table 8) was not lower than in PD patients 
(1.69±0.07), indicating preserved striatal dopamine D2 receptors. 
 
 
Table 8. Binding ratios for 123I-IBZM 
 
 
Patient 
dex sin  
Caudate/ 
OC 
Putamen/ 
OC 
Caudate/ 
OC 
Putamen/ 
OC 
Striatum total/OC 
1. 1.84 1.67 1.76 1.57 1.71 
2. 1.79 1.89 1.86 1.81 1.84 
3. 1.58 1.60 1.56 1.64 1.60 
4. 1.69 1.9 1.69 1.73 1.76 
5. 2.12 2.06 1.86 2.08 2.03 
6. 2.05 2.37 1.89 2.18 2.13 
7. 1.73 1.57 1.60 1.55 1.61 
8. 1.81 1.77 1.72 1.78 1.77 
 
OC – Occipital cortex 
 
 
5.7. Gene expression 
Comparison of the blood RNA samples isolated from methcathinone users and 
healthy controls revealed distinct gene expression profiles. Statistically signi-
ficant differential expression was observed for 326 genes, with the p-values less 
than 0.05 (FDR adjusted for multiple testing, Table 9). The magnitudes of 
expression signal differences (fold change or logFC) between these two groups 
were generally low: 17 genes were up-regulated in the methcathinone user more 
than 1.1-fold and only one gene was down-regulated more than 1.1-fold. 
However, the B-statistics values for the list of genes were very high, suggesting 
real biological differences between these groups. A heatmap (Figure 10) from 
unsupervised hierarchical clustering indicates clear clustering of samples into 
drug users and non-users. However, in the middle of the heatmap, some overlap 
and mixture between groups occurs. These samples are from methcathinone 
users with HIV negative status. Therefore, HIV status has a significant impact 
on the gene expression profile and is a strong confounding factor. 
A functional annotation analysis was performed to define gene networks 
within the observed expression profiles. Relationships among the 326 genes 
significantly different in the methcathinone users compared with the control 
43 
groups included two major networks. The first, (with the highest score of 47; 
score indicates the –log of enrichment p-value) contained genes annotated with 
cell death, antigen presentation, or neurological disease functions (Table 10A, 
Figure 11). A second network (score 42) was related to immunological disease, 
cellular movement, or cardiovascular disease. Enrichment or activation of these 
networks suggests that methcathinone users have changes in the genetic 
pathways related to the function of the nervous and immune systems.  
Table 9 includes many genes that are related to immune response, and may 
be differentially expressed compared with healthy controls because most of 
drug users were HIV positive. We therefore compared the subgroup of HIV 
negative drug users with the healthy control group. In this comparison, no genes 
were significantly different at FDR less than 5%, but 93 genes were different at 
or below a 30% FDR threshold. Annotation analysis for this dataset of HIV 
negative drug users indicated up-regulation (23 genes, score 54) in a network of 
genes with functions including hematological disease, cellular assembly and 
organization, or cell cycle (Table 10B). In another subgroup analysis we 
compared HIV positive subjects according to their user status, current versus 
discontinued. This comparison should indicate the difference caused by active 
drug abuse (Table 10C). In this case, both groups were HIV and HCV positive, 
so infection status was balanced. The most significantly enriched network in 
this comparison included genes in the Genetic Disorder, Immunological 
Disease, or Cellular Movement categories (25 genes, enrichment score 46). This 
network supports the involvement of the immune system in the drug abuse 
induced pathologies. 
To further verify changes found with the GeneChip experiment, we per-
formed quantitative real-time PCR and analyzed gene expression levels of eight 
selected genes. For seven genes, statistically significant differential expression 
between 20 healthy controls and 20 methcathinone users was seen in the 
expected direction of change (C15orf26 p<0.0001, GPR15 p<0.0001, IGFR1 
p=0.0002, SNRPN p=0.038, IFI44L p=0.0264, IFI27 p=0.0450, IFNG 
p<0.0001). These results support the validity of our microarray gene expression 
analysis. 
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Figure 10. Methcathinone users group distinctly on the hierarchical clustering heatmap 
of blood gene expression levels. The top 100 genes from the decreasing ordered list of 
moderated t-values were clustered according to similarity in their gene expression 
patterns. Signals are scaled to Z-scores of the rows. The colored bar above the heatmap 
indicates the grouping variable – goldenrod for methcathinone user, blue for controls. 
Column labels at the bottom combine HIV status (positive or negative) with the drug 
user status (current, past, never) 
47
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Figure 11. Annotation enrichment analysis indicated that a network including “cell 
death, antigen presentation, neurological disease” gene functions is significantly en-
riched in the subjects with methcathinone abuse (score 47, score is –log (p-value)).  Red 
nodes designate up-regulated genes and the number indicates log2 fold change (0 is for 
equal expression). Uncolored nodes are genes in this network that were not in our list of 
differentially expressed genes 
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6. DISCUSSION 
 
6.1. Clinical examination and laboratory tests 
Because cases of manganism appeared following long-term total parenteral 
nutrition [Nagatomo et al., 1999], a recommendation of 0.1 mg as the maximal 
intravenous daily supplementation of manganese serves as the guideline today 
[Bertinet et al., 2000]. It is interesting to compare this recommended load to that 
administered in the cases of the present study. A daily manganese load of 0.18 g 
can be roughly calculated from the concentration of 0.6 g/L obtained in the 
chemical analysis and an average daily injection volume of 0.3 L. This means 
that the subjects were exposed to an extreme manganese load – almost  
2,000 times higher than recommended. 
Manganism has been described in a variety of occupational and non-occu-
pational settings, but overt clinical manganism is rarely seen in current clinical 
practice. In our cohort, the syndrome was similar to parkinsonism reported in 
other ephedrone users and resembled classic Mn intoxication. The induced 
extrapyramidal syndrome tends to be symmetrical with bradykinesia, dystonias, 
early postural, gait, and speech impairment, and differs from the classical inital 
symptoms of PD. Rest tremor is rarely present and rigidity is mild. 
The disability in the ephedrone abusers is mainly caused by postural and gait 
impairment and dystonias in a relatively early phase of the disease. In UPDRS, 
only a few items in the motor score are related to gait and postural impairment, 
and there are more items for evaluation of tremor, which is not a characteristic 
sign for parkinsonism in ephedrone users. Combining UPDRS with HY staging, 
Schwab and England ADL rating scale, and PD Quality of Life Questionnaire 
provides better assessment of the syndrome severity. 
Symmetrical parkinsonism, usually without tremor, early falls, dysarthria, 
and dystonia are also characteristic symptoms of progressive supranuclear palsy 
(PSP) [Steele et al., 1964]. Vertical supranuclear-gaze palsy, a cardinal feature 
of PSP, was absent in our patients.  
Progressive hepatolenticular degeneration, or Wilson's disease (WD), a rare 
genetic disorder of copper metabolism with a wide range of clinical presen-
tations, including dystonia and parkinsonism, is another possible differential 
diagnosis. In tested study patients, copper and ceruloplasmin levels were 
normal. MRI in patients with WD has shown widespread lesions in the puta-
men, globus pallidus, caudate, thalamus, midbrain, pons, and cerebellum. Oppo-
site to Mn intoxication, these lesions show high-signal intensity on T2 weighted 
images and low-intensity on T1 scan [Ala et al., 2007].  
The quality of life is negatively influenced by disease severity, disability, 
and duration of exposure. The social situation is challenging in most abusers. In 
our patients, treatment with chelating agents was not suitable because Mn 
exposure in former users had stopped several years earlier and others continued 
ephedrone use, despite the substance abuse counselling. L-dopa, the mainstay 
treatment for PD, was not effective. Unresponsiveness to L-dopa has also been 
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confirmed in chronic occupational Mn intoxication [Lu et al., 1994]. We did not 
try L-dopa therapy in all of the subjects, becuse using prescribed dopamine 
enhancing drugs in HIV positive individuals could induce viral replication in 
the central nervous system [Gaskill et al., 2009]. 
The outcome of the neurological deficit after the cessation of ephedrone 
abuse is individual. Mild to moderate improvements have been observed in 
some cases [Levin, 2005; Sanotsky et al., 2007], but several cases progressions 
after withdrawal have been described [Colosimo and Guidi, 2009; Selikhova et 
al., 2008; Yildirim et al., 2009].  
The present study is the largest follow-up study of ephedrone users. No 
improvement was noted in active or former users, and some assessment scales 
indicated statistically significant worsening. In active users the worsening was 
not significant, but the follow-up time of about one year may be insufficient for 
revealing a slow progression. Former users had stopped ephedrone use on 
average four years before the baseline study. Despite the long duration of 
exposure cessation, their disabilty was still worsening. These findings indicate 
the possibilty that Mn exposure may trigger a chronic neurodegenerative pro-
cess. In a previous longitudinal study in four smelters with chronic Mn intoxi-
cation, a plateu occured after the initial ten years of disease progression [Huang 
et al., 2007].  
Parkinsonism is a common complication of an HIV infection. Parkinsonian 
features usually develop due to HIV-associated dementia or underlying 
opportunistic infections, but also may occur due to the HIV infection [Tse et al., 
2004]. Among the tested patients, 16 were HIV positive and 12 HIV negative. 
No MRI findings suggestive of opportunistic infections were found. Only one 
HIV positive patient had moderate cognitive impairment and in follow-up the 
score was surprisingly 25. There was no difference between the UPDRS scores 
of HIV positive and HIV negative patients. All of the tested patients were HCV 
positive, and a few of them had moderately increased alanine transaminase 
levels. Overt clinical signs or symptoms of hepatic cirrhosis were not noted. 
HIV and HCV infections do not cause the parkinsonian syndrome in ephedrone 
users, but in some cases possible additive effect on the developement of the 
syndrome cannot be ruled out.  
Mn is rapidly eliminated from plasma and subjects with exposure on the 
same day had significantly higher plasma concentrations than other active users. 
Hair Mn level remains higher for a longer period. In a Ukrainian study, patients 
who had been off ephedrone for over 2.5 years had some elevation in pubic hair 
Mn levels [Selikhova et al., 2008]. In our series, hair Mn concentration in 
former users was not different from controls, but the subjects had been drug free 
on average for 4.6 years. There is a large variability in mean values of hair Mn. 
At an individual level Mn concentrations are not reliable biomarkers of 
exposure, due to fast elimination from plasma and large variability in hair. 
Ephedrone users develop a distinctive extrapyramidal syndrome that is 
irreversible after the cessation of exposure, and there is a trend of worsening. 
Subjects are exposed to a high load of Mn and the clinical syndrome is similar 
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to classical manganism. The toxic role of Mn in the psychostimulant mixture is 
stressed by the fact that when during preparation potassium permanganate is 
substituted with sodium dichromate, sulfuric acid, acetone or toluene, the drug 
users avoid the extrapyramidal syndrome [Emerson and Cisek, 1993].  
Ephedrone addiction is an alarming new cause of toxic parkinsonism. 
Ephedrone is a widespread recreational drug because it is relatively cheap and 
easy to prepare. The described cases could be just “the tip of the iceberg”. In the 
most extreme cases, only a few months of ephedrone abuse could lead to severe 
and progressing disability. 
The prognosis of the parkinsonian syndrome in the ephedrone users is poor 
as there is no curative therapy. The addicts seem to be unaware of the long-term 
side effects and deterioration. Though presently reported mainly in Eastern 
Europe, a global spread might occur, and the diagnosis needs to be considered 
within the social risk groups anywhere. 
 
 
6.2. Neuroimaging 
Shortened T1 relaxation in two of the patients may be a sign of some remaining 
Mn, although the cessation of exposure was many years before and the plasma 
values of Mn were normal. Increased SI on T2-weighted images is a common 
finding in many pathological conditions e.g. in gliosis or demyelination. 
Decrease of SI on T2-weighted images is more uncommon. Most often 
shortening or lengthening of T1 and T2 relaxation times occurs simultaneously 
and is a non-specific sign of tissue damage or alteration. This might explain the 
changes in patient 1 and 3 (Table 4). In patient 2, the changes were in opposite 
directions. It is possible that Mn shortens the T1 relaxation time, but tissue 
injury may increase the T2 SI. Although the number of patients is small, we 
have shown that there are some changes in the basal ganglia. This is in accor-
dance with the few human neuropathological investigations which show clear 
evidence that the basal ganglia are primary targets for Mn neurotoxicity 
[Yamada et al., 1986]. 
Despite the neurological damage, cases which had stopped ephedrone abuse 
0.5 to 2 years before had normal MRI signals [Iqbal et al., 2012; Yildirim et al., 
2009]. However, in some studies, MRI signal change was still visible 3 to  
5 years after the cessation of ephedrone use [Selikhova et al., 2008; Stepens et 
al., 2008]. The localization of T1 hyperintense signal in our study was similar to 
previous reports, but increased signal in white matter has not been described 
before. Widespread white matter abnormalities in ephedrone users were 
previously demonstrated with diffusion tensor imaging [Stepens et al., 2010]. 
We divided the subjects into former and active users according to the 
information provided. However, some cases admitted continuing abuse after the 
MRI results were revealed. High signal in globus pallidus on MRI T1-weighted 
images in some reported former users (Table 7, case 5 and 11) might be due to 
continuing ephedrone abuse or to impaired liver function. Alanine transaminase 
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levels were moderately elevated in both cases. In summary, high MRI signal 
intensities on T1-weighted images reflect recent exposure to Mn, but normal 
findings do not exclude former exposure. High signal intensities several years 
after cessation of exposure should awake a suspicion of active abuse, unless 
other susceptibility factors like chronic liver disease are present.  
Besides Mn intoxication, another cause of pallidal T1 shortening is non-
ketotic hyperglycemia. Patients typically present with chorea and hemibal-
lismus. Follow-up neuroimaging usually shows the resolution of findings. The 
mechanism for the signal abnormalities is unkown. Depostition of proteins, 
myelin breakdown products, blood, or calcium or other minerals have been 
proposed [Lai et al., 1996]. 
Lasting reduction of DAT density has been shown in abstinent ephedrone 
and methamphetamine abusers without overt neurological or psychiatric illness 
by means of PET [McCann et al., 1998]. However, later studies in former 
methamphetamine abusers revealed significant recovery of DAT levels with 
protracted abstinence, suggesting that the changes were adaptive rather than 
neurotoxic [Volkow et al., 2001a]. Our normal DaTSCAN results indicate that 
the presynaptic neurons in the nigrostriatal pathway are intact in ephedrone 
abusers after prolonged abstinence. DAT SPECT studies in other ephedrone 
users have confirmed the normal integrity of the nigrostriatal dopaminergic 
terminals [Colosimo and Guidi, 2009; Selikhova et al., 2008]. Occupationally 
exposed workers with Mn-induced parkinsonism and patients with chronic liver 
disease had also normal DAT levels in the striatum [Huang, 2007; Kim et al., 
2007], whereas there is asymmetric loss of DAT in PD [Kagi et al., 2010]. 
Instead, there could be an impairment of dopamine release as shown in studies 
with non-human primates chronically exposed to Mn [Guilarte et al., 2008; 
Guilarte et al., 2006]. This theory might explain why our patients reported 
progressively weaker psychostimulatory effect of ephedrone, acting as a 
dopamine releaser. A recent study demonstrated that Mn promoted internali-
zation of the cell surface DAT into intracellular compartments, which may 
account for the decrease in dopamine uptake and release. When Mn and 
dopamine were added simultaneously to the media, cell toxicity was remarkably 
similar to that produced by Mn alone.  Preincubation of dopamine prior to the 
addition of Mn resulted in cell death which was essentially additive with that 
produced independently by the two agents [Roth et al., 2013]. Previous 
observations have demonstrated that DAT is required for, and dopamine is an 
essential mediator of, methamphetamine induced striatal dopaminergic neuro-
toxicity [Fumagalli et al., 1998]. Mn exposure could be protective against 
ephedrone induced alterations in dopaminergic nerve terminals.  
Untreated PD patients have normal or elevated levels of D2 receptors in the 
striatum [Brooks et al., 1992]. In atypical parkinsonian syndromes, D2 receptor 
bindings are usually decreased [Koch et al., 2007; Vlaar et al., 2008]. The 
present study shows no decrease in the level of postsynaptic D2 receptors in the 
striatum. 
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In typical idiopathic PD, glucose metabolism in the putamen and globus 
pallidus is preserved or raised, whereas it is reduced in most atypical parkin-
sonian cases [Brooks, 2010]. Detoxified methamphetamine abusers had higher 
metabolism in the parietal cortex and lower metabolism in the striatum and 
thalamus [Volkow et al., 2001b]. With protracted abstinence, there was signi-
ficant recovery of the thalamic, but no improvement in striatal metabolism 
[Wang et al., 2004]. A single study in humans with mild manganism showed 
decreased cortical metabolism [Wolters et al., 1989]. The results of our PET 
study showed a widespread non-uniform pathological subcortical affection of 
FDG uptake. Whether these changes are mainly manganese induced, as the 
clinical syndrome, or correspond to the effect of long-term ephedrone abuse 
cannot be concluded.  
Evidence from our neuroimaging studies support the hypothesis that 
accumulation of Mn in the brain is not associated with the degeneration of 
dopaminergic neurons as in PD, instead the dopaminergic system could be 
dysfunctional.  
  
6.3. Gene expression 
In this study, we examined changes in the gene expression profiles in peripheral 
blood induced by methcathinone abuse. All but one of the subjects had a 
clinically relevant extrapyramidal syndrome. RNA expression patterns of drug 
users clearly differed from those of healthy controls. Also, RT-PCR results 
confirmed differences between these two groups. The overlap between controls 
and HIV negative methcathinone users in the middle of the heatmap (Figure 10) 
suggested that most of the hierarchical clustering was driven by HIV infection 
status. During recent years several microarray studies of HIV induced 
alterations in host cell gene expression have been performed using in vitro 
infected primary cells, cell lines, or tissue samples [Giri et al., 2006]. However, 
few in vivo studies in HIV infected humans have evaluated expression profiles 
of tissue samples [Everall et al., 2005; Masliah et al., 2004] or peripheral blood 
mononuclear cells [Kottilil et al., 2009; Monaco et al., 2009; Motomura et al., 
2004]. Several of the same apoptosis, antigen presentation and immune 
response genes (IFIT3, IFI27, IFI44, IFNG, NFAT, STAT1, TCR, CCR5, ERK, 
IFITM3, LY6E, IFNG, NFkB, OAS1, PLSCR1) described in previous HIV 
microarray studies were upregulated in our analysis. Thus, peripheral blood can 
be used for finding gene expression alterations in HIV infected humans. Besides 
cell death and antigen presentation, the genetic network with the highest score 
was also related to neurological disease. HIV infection can lead to a syndrome 
of neurological dysfunction termed HIV-associated neurocognitive disorders 
(HAND). Multiplication of HIV infected macrophages/microglia could result in 
the release of HIV proteins such as gp120 and Tat, which can impair DAT 
function, leading to increased levels of dopamine. Accumulated synaptic 
dopamine can activate adjacent microglia, which may result in increased HIV 
replication and icreased production of inflammatory mediators. HIV proteins 
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and inflammatory mediators can induce apoptosis of adjacent dopamineric 
neurons [Purohit et al., 2011]. The use of psychostimulants is a major comorbi-
dity in the development of HAND. These drugs further increase extracellular 
dopamine, oxydative stress, and permeability of the blood-brain barrier, as well 
as exacerebrate the neurotoxic effects of gp120 [Silverstein et al., 2012]. 
Minor subgroup analysis of HIV negative users who were all positive for 
HCV indicated that genes related to cell cycle, cellular growth and proliferation, 
cancer, and cellular development were upregulated compared with healthy 
controls. The same pathways have been shown to be involved in HCV induced 
hepatic changes like cirrhosis, dysplasia, or hepatocellular carcinoma [De 
Giorgi et al., 2009; Wurmbach et al., 2007]. The presence of HCV co-infection 
among HIV-infected individuals increases neurologic disease burden and risk of 
death [Vivithanaporn et al., 2012]. The mechanism by which HCV contributes 
to that is not well defined, but there is evidence to suggest that HCV does 
invade the brain where it may exacerbate the neurotoxic inflammatory response 
[Laskus et al., 2005]. 
As the aim of our study was to analyze the drug abuse effect, we decided to 
stratify our group of subjects. We analyzed only HIV and HCV positive 
subjects according to their injection status (past versus current) and a clinical 
measure of the severity of the neurological syndrome UPDRS. The most 
significantly enriched network after comparing HIV positive current and past 
users included genes annotated with functions in Genetic Disorder, Immuno-
logical Disease, or Cellular Movement categories (25 genes, enrichment score 
46). This network confirms the involvement of the immune system in drug 
abuse induced pathologies. However, as both comparison groups had neuro-
logical symptoms, we can’t draw any conclusions on the potential causes of the 
extrapyramidal syndrome. On the other hand, injection status seems to influence 
the immune system and this is one factor involved in the development of a 
neurodegenerative syndrome [Frank-Cannon et al., 2009]. Psychostimulant 
abuse has been shown to compromise immunological status [Everall et al., 
2005]. Chronic Mn exposure has similar effects on the immune system 
[Guilarte et al., 2008b; Sengupta et al., 2007]. Thus, both of these factors have 
potential to induce neurodegeneration. 
The UPDRS score reflects the clinical severity of the extrapyramidal 
syndrome. No significant correlations were found between the duration of Mn-
methcathinone use and UPDRS, or between blood RNA profiles and UPDRS.  
There are several limitations to our study. The main problem is related to the 
sample organization. Our sample contains many confounding factors – HIV and 
HCV infection, different duration of methcathinone use, concomitant con-
sumption of other drugs, alcohol, and tobacco. We have not analyzed the 
clinical status of the HIV and HCV infections. In addition, several drug abusers 
were undernourished, which makes identification of a relevant control group 
even more complicated. To overcome these limitations, we have applied 
complex bioinformatics analytical tools in relatively large samples (N=20 in 
both groups) that allowed us to perform some cohort stratification.  
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6.4. Future prospects 
Though parkinsonism is not a feature of ephedrone abuse, it remains possible 
that the induced profound depletion of catecholamines could increase the 
vulnerability to extrapyramidal damage. To clarify the pathogenetic mecha-
nisms underlying combined Mn and ephedrone toxicity experimental animal 
studies are being carried out. Very valuable would be an autopsy neuropatho-
logical study in humans. 
For cases with severe generalized dystonia deep brain stimulation (DBS) 
could be a treatment option. DBS has been used successfully in various forms 
of dystonia, especially in the treatment of primary generalized dystonias [Volk-
mann et al., 2012], but improvement in secondary dystonias has been shown  as 
well [Katsakiori et al., 2009]. 
Longer follow-up periods in former ephedrone users are necessary to 
provide information about the duration of progression or reversibility. 
Ephderone users comprise a very important  study cohort to understand the 
molecular mechanisms by which chronic exposure to Mn alters neurochemical 
pathways in the brain. Measuring the in vivo dopamine release using 
amphetamine-induced PET in ephedrone users could provide further infor-
mation about Mn neurotoxicity, but there are ethical problems in giving 
amphetamine to the former users and difficulties in making arrangements with 
the current users. 
Transcranial sonography can detect trace metal accumulation in deep brain 
structures with higher sensitivity than conventional MRI, as elevated trace metal 
content leads to an increased echogenicity. Hyperechogenicicity of the globus 
pallidus was detected in two patients with welding-related parkinsonism with 
normal MRI. Substantia nigra hyperechogenicity, characteristic for idiopathic 
PD, was absent in those patients [Walter et al., 2008]. Whether or not transcra-
nial sonography of the former ephedrone users can be useful for detecting Mn 
accumulation and can differentiate it from PD, needs to be confirmed in future 
studies.   
For further gene expression studies within similar populations, more 
balanced control samples are needed (e.g. drug-free HIV positive subjects, or 
comparison with other drug abusers). It would be useful to evaluate CD4 counts 
in HIV positive subjects to assess the immune system. Body mass index and 
plasma albumin measuring are simple means to diagnose malnutrition. 
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7. CONCLUSIONS 
 
1. Ephedrone users develop a distinctive extrapyramidal syndrome that re-
sembles classic Mn intoxication. The most prevalent symptoms are symmet-
rical bradykinesia, dystonias, early postural, gait, and speech impairment. 
Unlike what is seen in patients with idiopatic PD, rest tremor is rarely 
present and rigidity is mild; levodopa therapy is not effective. 
 
2. Most of subjects have a disability that interferes with their activities of daily 
living and impairs the quality of life. Syndrome severity was not influenced 
by the duration of exposure; i.e., a severe motor impairment could develop 
only after a short time of ephedrone abuse. The syndrome is irreversible after 
cessation of exposure and there is a trend of worsening.  
 
3. The injected solution contains high concentration of Mn. At an individual 
level, Mn concentrations are not reliable biomarkers of exposure, due to fast 
elimination from plasma and large variability in hair. High MRI signal 
intensities on T1-weighted images reflect recent exposure to Mn; normal 
findings do not exclude former exposure. High signal intensities several 
years after cessation of exposure should awake a suspicion of active abuse, 
unless other susceptibility factors like chronic liver disease are present. 
 
4. MRI showed that Mn accumulates in globus pallidus, substantia nigra, 
periaquaductal grey matter, and cerebral pedunculi, and less in putamen, 
caudate nucleus, dentate nucleus and white matter. Functional imaging 
results indicate that the pre- and postsynaptic neurons in the nigrostriatal 
pathway are intact in ephedrone abusers. FDG PET demonstrated decreased 
brain metabolism mainly in the central part of the brain, including the basal 
ganglia, thalami, and the surrounding white matter. 
 
5. Ephedrone users and healthy controls have distinct gene expression profiles, 
with most of the differences driven by HIV and HCV infection status. 
Comparing active and former HIV and HCV positive ephedrone users 
revealed involvement of the immune system and this is one factor involved 
in the development of a neurodegenerative syndrome. 
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9. SUMMARY IN ESTONIAN 
 
Mangaani ja efedrooni intoksikatsioonist tingitud 
neuroloogilise kahjustuse patogenees ning  
kliiniline sümptomaatika 
Parkinonistlike sündroomide põhjuseid on palju, Parkinsoni tõbi on nendest 
kõige sagedasem. Parkinsoni tõve standarditud levimus Eestis Tartu 
populatsiooniuuringu andmetel oli 152 juhtu 100 000 elaniku kohta, sealjuures 
vanusespetsiifiline levimuskordaja alla 39-aastaste vanuserühmas oli 0 [Taba ja 
Asser, 2002]. Parkinsonistlikud sündroomid võivad tekkida ka teistel põhjustel: 
neurodegeneratiivsete haiguste, ravimite, aju koldeliste kahjustuste, 
vaskulaarsete haiguste, infektsioonide ja toksiinide tõttu [Cersosimo ja Koller, 
2006]. Mangaanimürgistusega seotud parkinsonismi kirjeldati esimest korda 
juba 1837. aastal mangaanikaevanduse töölistel [Couper, 1837]. Kirjanduses 
kõige rohkem rõhutatud manganismi põhjuseks ongi mangaanikaevandustes 
töötamine [Mena jt, 1967] ja ka keevituselektroodide kasutamine [Koller jt, 
2004]. Suu kaudu manustatuna ja inhaleerituna jõuab kesknärvisüsteemi ainult 
väike kogus mangaani, mistõttu neurotoksilisus on küllaltki harv ja tekib 
pikaaegse ekspositsiooni järel või kaasuva maksapuudulikkuse korral [Jankovic, 
2005]. On mõned näited sümptomite arengust täielikul parenteraalsel toitmisel 
olnud patsientidel [Ejima jt, 1992]. 
Alates 1990. aastate lõpust on Eesti neuroloogide poole pöördunud parkin-
sonistliku sündroomiga noori patsiente. Esimeste haigete pöördumisel oli 
keeruline tuvastada haiguse tekkepõhjust, kuid hiljem selgus, et need patsiendid 
olid eelnevalt mingi aja jooksul intravenoosselt manustanud n-ö kodumeetodil 
valmistatud pseudoefedriini, kaaliumpermanganaadi, äädikhappe ja keeva vee 
segu. Pseudoefedriini sisaldavad mitmed nohu sümptomaatiliseks raviks näidus-
tatud käsimüügipreparaadid. Kaaliumpermanganaat on tugev oksüdeerija. 
Reaktsiooni tulemusel tekib pseudoefedriinist efedroon ehk metkatinoon. Efed-
roon on psühhostimulant, mille toime on sarnane metamfetamiiniga, kuid ena-
masti vähem intensiivne. Toksilise kõrvalproduktina sisaldab valmis narkoo-
tiline segu ka mangaani. 
Enne uuringu alustamist puudusid rahvusvahelises kirjanduses viited, et 
efedrooni tarvitamine on üks võimalik parkinsonismi tekkepõhjus. Kuigi 
psühhostimulandid mõjuvad dopaminergilistele neuronitele toksiliselt, ei arene 
tarvitajatel parkinsonistlikku sündroomi [Guilarte, 2001]. Samuti ei olnud 
varem kirjeldatud narkootikumide tarvitamist manganismi võimaliku põhjusena. 
Eestis oli 2007. aastal Tallinna ning Ida-Virumaa süstivate narkomaanide 
seas korraldatud uuringu andmetel 700 küsitletu hulgas 11% (n = 76) neid, kes 
olid tunnistanud efedroonisegu tarvitamist, kuid peamiseks narkootikumiks oli 
efedroon vähem kui 1%-l (n = 6) [Lõhmus jt, 2008]. Tervise Arengu Instituudi 
hinnangu kohaselt on Eestis ca 13 800 süstivat narkomaani. Seega võiks isikuid, 
kes peamise narkootikumina süstivad efedrooni, olla Eestis umbes sadakond. 
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Uurimistöö eesmärgid 
1. Kirjeldada efedrooni süstijatel esinevat neuroloogilist sündroomi ning hin-
nata spetsiaalsete skaalade abil parkinsonistlikku sündroomi, haiguse 
raskusastet ja elukvaliteeti. 
2. Uurida efedrooni tarvitajatel neuroloogilise sündroomi kulgu. 
3. Leida segu tarvitamise kindlakstegemiseks iseloomulikud biomarkerid. 
4. Kirjeldada muutusi magnetresonantstomograafilises (MRT) ja funktsio-
naalsetes radioloogilistes uuringutes. 
5. Teostada perifeerse vere geeniekspressiooni analüüs, et selgitada neuroloo-
gilise kahjustuse molekulaarset patogeneesi. 
 
 
Uuritavad ja meetodid 
Uuringu kiitis heaks Tartu Ülikooli inimuuringute eetika komitee. Kõik uurin-
gus osalejad allkirjastasid teadliku nõusoleku vormi. Uuritavate kontaktandmed 
saadi Eesti suuremate haiglate neuroloogia ja psühhiaatria osakondade arstidelt, 
narkomaania rehabilitatsiooni keskustest ja efedrooni tarvitajatelt. 
Haigeid intervjueeriti ning hinnati nende kliinilist neuroloogilist leidu, 
enamiku uuritavate neuroloogilist sündroomi ka filmiti. Hinnati parkinsonist-
likku staatust, haiguse raskusastet, elukvaliteeti ja kognitiivset funktsiooni. 
Selleks kasutati järgmisi rahvusvaheliselt tunnustatud skaalasid: Parkinsoni tõve 
hindamise ühtlustatud skaala (UPDRS), Hoehni-Yahri skaala (HY), Schwabi-
Englandi (SE) igapäevaste tegevuste skaala [Fahn S jt, 1987], Parkinsoni tõve 
elukvaliteedi küsimustik (PDQ-39) [Peto jt, 1995] ning vaimse seisundi mini-
uuring (MMSE) [Folstein jt, 1975]. 
UPDRS koosneb 31 osast, millest iga alajaotus annab 0 kuni 4 punkti, 
lähtudes sümptomi raskusest (0 – normaalne, 4 – väga väljendunud). Kogu testi 
maksimumskoor on 176 punkti. HY skaalaga hinnatakse haiguse raskusastet, 
võttes aluseks kliinilise leiu ja funktsionaalse võimekuse. HY skaala sisaldab 
staadiume 0 (leiuta) kuni 5 (ratastoolis või voodis; abitu). SE igapäevaste 
tegevuste skaala abil hinnatakse inimese iseseisvust protsentuaalselt 0 kuni 
100%-ni (100% – täiesti iseseisev, ei tunneta mingeid raskusi; 0% – säilinud 
ainult vegetatiivsed funktsioonid). PDQ-39 on samuti protsentuaalne skaala, 
milles suurim tulemus näitab kehvimat hinnangut elukvaliteedile. MMSE 
maksimaalne tulemus on 30 punkti, normiks peetakse vahemikku 25 kuni 30. 
Levodopa raviefekti hindamiseks tehti neljale uuritavale levodopa (200 mg) ja 
karbidopa (50 mg) standarditud provokatsioonitest, mille tulemust hinnati ühe 
tunni möödumisel. 
Korduvalt testiti 24 patsienti, keskmiselt 21 ± 15 kuud pärast esimest hinda-
mist, sh 12 endist ja 12 narkootilise segu aktiivset tarvitajat. 
Narkootilise segu süntees ja keemiline analüüs tehti Uppsala Ülikooli 
analüütilise keemia osakonnas. Sünteesitud efedrooni analüüsiti kvalitatiivselt 
elektropihustus-ionisatsiooni-mass-spektromeetriga. Mangaani (Mn 54,9) sisal-
dust lõpplahuses mõõdeti induktiivse plasma aatomemissioon-spektromeetriga. 
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Plasma (n = 26) ning karvade (juukse- + kubemekarvade) (n = 17) Mn-
kontsentratsiooni analüüsiti induktiivse plasma aatomemissioon-spektro-
meetriga. Kontrolliks analüüsiti soo ja vanuse poolest sobitatud 21 Ida-Virumaa 
elaniku karvu.  
Uppsala Ülikooli neuroteaduste osakonnas tehti MRT koos T1-signaali 
relaksatsiooniaja mõõtmisega; ioflupaaniga (123I Ioflupane) üksikfooton-
emissioon-kompuutertomograafiline (SPECT) uuring ning positronemissioon-
tomograafiline uuring 2-desoksü-fluoro-D-glükoosiga (FDG-PET) neljal 
patsiendil, kes polnud efedrooni tarvitanud vähemalt neli aastat.  
IBZMiga (123I-iodobensamiid) SPECT (n = 8) ja MRT uuringud (n = 11, sh 
aktiivsed kasutajad) tehti Põhja-Eesti Regionaalhaiglas.  
20 patsiendil ja 20 kontrollisikul eraldati RNA, tehti globiini redutseerimine 
ja hinnati geeniekspressiooni analüsaatoriga Affymetrix GeneChip. Kontrol-
lidega võrreldes erinevalt avaldunud geenidest valiti välja 8 geeni, mille tule-
mused kinnitati kvantitatiivselt reaalaja PCRiga.  
 
 
Uurimistöö tulemused ja arutelu 
Ajavahemikul 2006–2012 uuriti kokku 38 patsienti, neist 31 meest ja 7 naist, 
kelle keskmine vanus oli 33 aastat (vahemikus 18–58 aastat). Põhiliselt olid 
patsiendid pärit Ida-Virumaalt (n = 29, 76%), väiksem osa Tallinnast ja 
Harjumaalt (n = 7, 18%), kaks Tartust. Peamiselt olid efedrooni tarvitajate 
hulgas vene rahvuse esindajad (97%), üks uuritav oli eestlane. Enamik patsiente 
oli koolis käinud kuni 9. klassini ehk oli põhiharidusega või alla selle (n = 25; 
66%), 6 patsiendil oli keskharidus, 6-l kutseharidus ja ühel patsiendil kõrg-
haridus. 95% patsientidest olid töötud, 70%-l oli vormistatud invaliidsus-
pension. Abielus oli 10 patsienti, nendest 8 juhul olid mõlemad partnerid 
uuritavad. Suurem osa patsientidest olid vallalised (58%) või lahutatud (16%). 
Uurimise ajal elas sotsiaalmajas 32% patsientidest, kaks olid vanglas ja ühel 
kindel elukoht puudus. Ligikaudu pooled efedrooni tarvitajatest elasid üksi 
(46%), neljandik elas koos vanema(te)ga ja neljandik koos abikaasaga, 
viiendikul kuulus(id) perekonda ka laps(ed). 
Patsiendid jagati neilt saadud anamneesi alusel kas aktiivseteks (n = 20) või 
endisteks (n = 18) efedrooni tarvitajateks (lõpetasid segu tarvitamise vähemalt 
üks aasta varem, keskmiselt olid nad lõpetanud selle 4,9 ± 2,2 a varem). 
Intravenoosselt olid nad süstinud korraga 8 kuni 20 ml paar kuni mitukümmend 
korda päevas. Segu komponentide vahekord (eelkõige kaaliumpermanganaadi 
osa) erines patsienditi veidi. Efedroon oli peamine tarvitatav narkootikum. Teisi 
stimulante (peamiselt amfetamiini) olid proovinud pooled narkomaanid ning 
63% olid tarvitanud ka opiaaate (heroiini, fentanüüli ja moonivedelikku). Vanus 
efedrooni tarvitamise alustamisel oli 25 aastat (vahemikus 14 kuni 41 aastat). 
Kõige parema ülevaate mangaani võimalikust üldekspositsioonist andis 
efedrooni kasutamise kestus, mis oli keskmiselt 4,6 ± 3,9 aastat (0,25 kuni 13). 
Esimesed neuroloogilised kaebused tekkisid 2,8 ± 3,1 aastat (mõne kuu kuni 12 
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aasta jooksul) pärast tarvitamise alustamist. Esmassümptomiks märgiti 37% 
juhul kõnnaku muutus, 26%-l kõne muutus ja 24%-l tasakaaluhäire.  
Uuritavate UPDRS-skoor oli keskmiselt 43 ± 21 punkti, millest UPDRSi III 
osa (motoorika) andis kokku keskmiselt 28 ± 15 punkti. UPDRSi III osa alusel 
olid peamisteks sümptomiteks jäsemete sümmeetriline bradükineesia (keskmine 
skoor 2,29 skaalal 0–4), posturaalsed (2,26), kõnnaku- (2,07) ja kõnehäired 
(2,33). Rahutreemorit enamasti ei ilmnenud (0,16) ja rigiidsust oli harva (0,69). 
Lisaks esines sageli jäsemete düstooniat, mida UPDRSi III-ga ei hinnata. 
Kliinilise raskusastme järgi klassifitseerusid pooled patsientidest HY skaala 
alusel III staadiumisse (kerge kuni mõõdukas kahepoolne haigus; mõningane 
posturaalne ebastabiilsus; füüsiliselt sõltumatu). SE skaalal oli keskmine 
tulemus 76 ± 15% (mitte täiesti iseseisev; mõnede tegevustega rohkem raskusi; 
ajakulu on kaks kuni korda suurem kui tavaliselt; suur osa päevast kulub 
igapäevastele kodustele töödele). Elukvaliteedi küsimustiku PDQ-39 keskmine 
skoor oli 43 ± 18%. Kõige halvem oli hinnang elukvaliteedile füüsilise või-
mekuse (53%), emotsionaalse heaolu (55%), stigma (53%) ja suhtlemise (52%) 
alaosades. Elukvaliteet sõltus UPDRSi, HY ja SE skaala tulemustest. Inimese 
immuunpuudulikkuse viirusega (HIV) nakatunute elukvaliteet ei olnud halvem 
võrreldes HIVga mittenakatunutega. Seost süstimise kestuse ja kliinilise leiu 
raskuse (mõõdetuna UPDRSi, HY ja SE skaalaga) vahel ei olnud, kuid esines 
tarvitamise kestuse ja elukvaliteedi seos (r = 0,41; p = 0,014). MMSE keskmine 
tulemus oli 28,4 ± 2,0. Kahe uuritava punktisumma jäi alla 25, mis viitab 
kognitiivsele defitsiidile. Standarditud levodopatest ei näidanud objektiivset ega 
subjektiivset paranemist. 
Korduvalt testimisel oli kõikide skaalade keskmine muutus patsiendi kohta 
halvenenud, HY (p = 0,026) ja SE (p = 0,006) skaala puhul oli halvenemine 
statistiliselt oluline. Kõikide skaalade muutus, v.a MMSE, oli oluliselt suurem, 
kui kahe testimise vahe oli pikem. Aktiivsete tarvitajate skaalade muutus ei 
olnud suurem kui endistel tarvitajatel, kuid aeg korduva testimiseni oli neil 
lühem. 
Ligikaudu pool pseudoefedriinist (44%) oksüdeerus efedrooniks. Segu 
mangaanisisaldus oli 595 ppm ehk 0,6 g/l. Ravijuhendi järgi ei tohiks täielikult 
parenteraalsel toitmisel olevate patsientide maksimaalne päevane Mn-annus 
ületada 0,1 mg [Bertinet jt, 2000]. Uuritavad süstisid päevas umbkaudu 0,3 l 
lahust, seega kokku ca 180 mg mangaani, mida on soovituslikust päevaannusest 
ligi 2000 korda enam. 
Patsiendid, kellele oli võimalik teha vereanalüüs viirusmarkerite määra-
miseks (n = 28), olid kõik nakatunud C-hepatiidiga ning 64% neist oli naka-
tunud B-hepatiidiga (HbsAg ja/või anti-HBc marker olid positiivsed) ja 57% 
olid HIV-positiivsed. Ühelgi uuritaval ei esinenud transaminaaside aktiivsuse 
väljendunud suurenemist ega maksatsirroosi kliinilisi sümptomeid. Rauavaegus 
(raua ja ferritiini sisalduse vähenemine ning transferriinisisalduse suurenemine) 
esines ühel patsiendil. 
Uuritavate Mn-kontsentratsioon karvades (2,9 ± 3,8 ppm) oli oluliselt suu-
rem kui kontrollidel (0,82 ± 1,02 ppm), p = 0,02. Endiste tarvitajate ja 
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kontrollide vahel erinevust ei olnud (1,08 ± 0,4; p = 0,56) ning see oli tõe-
näoliselt tingitud sellest, et endised tarvitajad olid süstimise lõpetanud kesk-
miselt juba 4,6 aastat enne proovide kogumist. Individuaalselt hinnatuna oli 
karvade Mn-kontsentratsioon väga erinev, kontrollrühma suurim väärtus oli  
4,5 ppm. Samas oli ühe suure plasmakontsentratsiooniga aktiivse tarvitaja Mn-
tase karvades madal (0,81 ppm).  
Aktiivsete tarvitajate plasma Mn-kontsentratsioon (11,5 ± 6,2 ppb) oli oluliselt 
suurem kui endistel tarvitajatel (5,6 ± 1,8 ppb); p = 0,006. Samal päeval efedrooni 
süstinud aktiivsete tarvitajate (n = 5) keskmine plasma Mn-kontsentratsioon oli 
18,3 ± 5,5 ppb ja teistel aktiivsetel tarvitajatel 8,1 ± 2,7; p = 0,0003. Erinevus 
analüüside võtmisega samal päeval mittesüstinud aktiivsete tarvitajate ja endiste 
tarvitajate vahel oli ka oluline, kuid palju väiksem (p = 0,02). 
MRT T1- ja T2-signaaliga relaksatsiooniajad basaaltuumades erinesid kolmel 
patsiendil kontrollidest enam kui 2 standardhälvet. See võib viidata vähesele Mn-
jäägile, kuid sobib ka mittespetsiifilisele koekahjustusele või muutusele. Üksikud 
neuropatoloogilised uuringud inimestel Mn-mürgistuse korral on samuti 
näidanud, et peamiselt on kahjustatud basaaltuumad [Yamada jt, 1986]. 
Dopamiini transportijate (DAT) ioflupaaniga SPECT-uuringu alusel ei esine-
nud uuritavatel presünaptilist dopaminergilist kahjustust. Ka mangaanimürgis-
tusega seotud parkinsonismi korral töölistel või kroonilise maksahaigusega 
patsientidel on DAT-tase olnud striatum’is normis [Huang, 2007; Kim jt, 2007]. 
Parkinsoni tõve korral on DAT-tase asümmeetriliselt alanenud ja dopamiini 2. 
tüüpi (D2) resteptorite tase striatum’is normis [Kagi jt, 2010]. Atüüpilise 
parkinsonismi puhul on enamasti striatum’i D2-retseptorites märkaine kogune-
mine alanenud [Koch jt, 2007; Vlaar jt, 2008]. Efedrooni tarvitajatel tuli 
IBZMiga SPECT-uuringul nähtavale normaalne sümmeetriline märkaine kogu-
nemine striatum’ite projektsioonis. 
FDG-PET-uuring viitas laialdasele, kuid mittespetsiifilisele aju metabolismi 
aeglustumisele peamiselt basaaltuumades, talamustes ja ümbritsevas valgeaines. 
Pole võimalik järeldada, kas muutused on tingitud mangaani või efedrooni 
kahjustusest. Püsivat striatum’i metabolismi aeglustumist on täheldatud ka 
endistel metamfetamiini tarvitajatel [Wang jt, 2004]. 
Kõigil aktiivsetel kasutajatel oli MRT-leid sarnane: sümmeetriline T1-
signaali hüperintensiivsus peamiselt pallidum’is, substantia nigra’s, ajuveejuha 
ümbruses hallaines ja ajujalakestes, vähem putamen’is, nucleus caudatus’es, 
nucleus dentatus’es ja valgeaines. Enamikul endistel tarvitajatel oli signaali 
intensiivsus normaliseerunud.  
Analüüsitud 28 869 geenist oli 326 geeni avaldumus patsientidel ja kontroll-
rühmas statistiliselt erinev. Tulemusi analüüsides selgus, et enamik erinevustest 
oli seotud patsientide HIV-positiivsusega. Seetõttu võrreldi järgnevas analüüsis 
ainult HIV-negatiivseid patsiente (n = 5) kontrollidega. Selgus, et erinevalt oli 
avaldunud 93 geeni. Kasutades analüütilist tarkvara Ingenuity Pathway Analysis 
(IPA), leiti, et aktiveeritud olid geneetilised rajad, mis on seotud hemato-
loogiliste haigustega, rakutsükli reguleerimisega ja aminohapete metabolismiga. 
Järgnevalt võrreldi omavahel aktiivseid ja endisi HIV-positiivseid tarvitajaid 
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(selles võrdluses olid mõlema rühma uuritavad HIV- ja C-hepatiidi viiruse 
suhtes (HCV) positiivsed ehk infektsiooni staatus oli balansseeritud). Selles 
võrdluses tuli esile geneetiline rada, mis on seotud geneetiliste häirete, immuno-
loogiliste haiguste ja rakulise liikumisega. Et tuvastada, millised muutused on 
olulised kliinilise sündroomi tekkes, rakendati HIV-positiivsete geeniekspres-
siooni väärtuste ja UPDRS-skoori suhtes lineaarset regressiooni. Mitmete 
geenide väljendumismuster oli seotud kliinilise raskusastmega, kuid kahjuks 
puudusid paljude geenide kohta selged annotatsioonid, mistõttu ei olnud 
vastavaid geene võimalik leida ja ka statistiline erinevus polnud eriti suur. 
 
 
Uurimistöö järeldused 
1. Efedrooni tarvitajatel tekib parkinsonistlik sündroom, mis sarnaneb man-
gaani klassikalise intoksikatsiooniga. Enam väljendunud sümptomid on 
sümmeetriline bradükineesia, düstooniad, varased kõnnaku-, posturaalsed ja 
kõnehäired. Idiopaatilisest Parkinsoni tõvest erineb kliiniline pilt eelkõige 
enamasti rahutreemori ja rigiidsuse harva esinemise ning L-dopa raviefekti 
puudumise tõttu. Enamikul efedrooni tarvitajatel on puue, mis segab iga-
päevaeluga toimetulekut ja halvendab elukvaliteeti. 
2. Puudub seos efedrooni kasutamise kestuse ja haiguse kliinilise raskuse vahel 
ehk ka siis, kui narkootikumi tarvitada väga lühikese perioodi jooksul, võib 
tarvitamise järel tekkida raske motoorne defitsiit. Kahjustus on pöördumatu 
ja haiguse progresseerumise tendents esineb ka pärast tarvitamise lõpetamist. 
3. Süstitava segu mangaanisisaldus on suur, uuritavad on eksponeeritud 
mangaanisisalduse soovituslikust normist ligi 2000 korda suurematele 
väärtustele. Individuaalsel tasemel on efedrooni tarvitamist raske kindlaks 
teha. Veres on mangaani metabolism kiire ja enamasti plasma mangaani-
väärtused normaliseeruvad ruttu. Juuksekarvades püsib suur mangaani-
kontsentratsioon kauem, kuid esineb suur normiväärtuste variaablus. MRT 
T1-signaali intensiivsuse suurenemine pallidum’is viitab mangaanieksposit-
sioonile, normileid ei välista varasemat kokkupuudet. MRT T1-signaali 
hüperintensiivsus aastaid pärast efedrooni tarvitamise lõppu võib viidata 
narkootikumi tarvitamise jätkumisele, kui ei kaasne teisi mangaaniladestu-
mist soodustavaid tegureid, näiteks maksapuudulikkust. 
4. MRT-uuringute tulemused näitavad, et mangaan ladestub peamiselt palli-
dum’is, substantia nigra’s, ajuveejuha ümbruses hallaines ja ajujalakestes. 
Pre- ja postsünaptilises dopaminergilistes retseptorites olulist defekti ei ole, 
võimalik, et kahjustatud on dopamiini vabanemine. FDG-PET-uuringu tule-
mused näitavad aju ainevahetuse aeglustumist peamiselt basaaltuumades, 
talamuses ning neid ümbritsevas valgeaines. 
5. Efedrooni tarvitajate ja kontrollrühma geeniekspressiooni profiil on erinev. 
See tuleneb peamiselt uuritavatel kaasuvatest HIV- ja HCV-infektsioonidest. 
Võrreldes aktiivseid ja endiseid tarvitajaid (mõlemad rühmad ka HIV- ja 
HCV-positiivsed), oli praegustel tarvitajatel immuunsüsteem aktiveerunud. 
Immuunsüsteemil on oluline roll ka neurodegeneratiivsete haiguste tekkes. 
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